Immediate release nephetipene. Why?
It's been associated with an increased risk of stroke in this setting. So stick to the longer acting formulations if you need a dihydrop.
Okay, that's a serious red flag to remember. Immediate release nettine is out. What about ACE inhibitors? When do they come into play?
ACE inhibitors are crucial. for reducing mortality particularly in patients who have evidence of left ventricular systolic dysfunction. So reduced ejection fraction or signs of heart failure or diabetes or if they've had a recent MI.
So specific groups benefit most.
Yes. And ideally they should be started within 24 hours in these high-risisk groups. ARBs are the alternative if ACEs aren't tolerated.
Now let's talk clots. Preventing those crucial clots from forming are getting bigger. What's the strategy for anti-coagulation and anti-platlet therapy in and STEMI
absolutely essential part of management for anti-coagulation. Hepins are a cornerstone and oxiparin which is a low molecular weight hepin or LMW is generally preferred over unfractionated hepin UFH.
Why is an oxiparin preferred?
Mainly because it has a more predictable anti-coagulant response and it's easier to administer subcutaneous injections versus an IV infusion that needs monitoring.
Easier. Okay. Any exceptions?
Yes. The big one is significant renal dysfunction. If the creatinine clearance is below 30 molan, then unfractionated hepin is generally the safer choice because it clearance isn't kidney dependent.
Good point. Renal function matters. Any other anti-coagulants?
Fontaranex is another option. It's an indirect factor as a inhibitor. It's also effective and notably it seems to have a lower bleeding incidence compared to an oxiparin in some studies.
Lower bleeding. That's good. Okay. And for antiplatlets, we know ASA is key.
ASA is foundational. Yes. Started promptly, continued longterm. Usually 81 milligram daily long-term after an initial loading dose but it's typically combined with a second antipllet agent
and that's where the P2Y12 inhibitors come in clapitol tagrreller prashugril
exactly clidal was the first big one shown to provide benefit when added to ASA significantly reducing adverse cardiac events
but there's a catch with clapidogil right the genetics
yes that's a key nuance its effectiveness can be diminished in patients who are poor metabolizers due to certain genetic vari in the CYP2C19 enzyme which is needed to activate the drug.
Do we test for that routinely?
No. Routine genetic testing isn't currently recommended across the board, but it's an important factor to consider. If a patient isn't responding as expected or if they have a spent thrombosis despite being on clapadogil
okay so that led to the newer more potent options like prashagil and teagural what makes them different
precisely prugil is more potent than clopedogil but that potency comes with a significantly increased risk of bleeding
more bleeding risk. especially in older patients, those with low body weight or anyone with a prior history of stroke or TIA. It's actually contraindicated in patients with prior stroke IIA. So, its use is generally more restricted, often considered in higher risk patients undergoing PCI, particularly if they're getting a stent and are at high risk for stent thrombosis.
So, careful patient selection for proagril. What about teagur?
Togagler is also more potent than clapadigril and it has an advantage in that it doesn't require metabolic activation. So its onset and offset are faster and perhaps more predictable.
No activation needed,
right? Studies like Plato showed it led to lower rates of cardiovascular death, MI or stroke compared to Clapopil.
That sounds good. Downsides.
It does come with an increase in non-annabi related major bleeding. And a fairly common side effect is dysmia or shortness of breath which can sometimes lead to patients needing to switch therapy.
Dysmia. Okay. Wow, that's a lot of detail on the antiplatlets, but it's clearly critical.
It's been associated with an increased risk of stroke in this setting. So stick to the longer acting formulations if you need a dihydrop.
Okay, that's a serious red flag to remember. Immediate release nettine is out. What about ACE inhibitors? When do they come into play?
ACE inhibitors are crucial. for reducing mortality particularly in patients who have evidence of left ventricular systolic dysfunction. So reduced ejection fraction or signs of heart failure or diabetes or if they've had a recent MI.
So specific groups benefit most.
Yes. And ideally they should be started within 24 hours in these high-risisk groups. ARBs are the alternative if ACEs aren't tolerated.
Now let's talk clots. Preventing those crucial clots from forming are getting bigger. What's the strategy for anti-coagulation and anti-platlet therapy in and STEMI
absolutely essential part of management for anti-coagulation. Hepins are a cornerstone and oxiparin which is a low molecular weight hepin or LMW is generally preferred over unfractionated hepin UFH.
Why is an oxiparin preferred?
Mainly because it has a more predictable anti-coagulant response and it's easier to administer subcutaneous injections versus an IV infusion that needs monitoring.
Easier. Okay. Any exceptions?
Yes. The big one is significant renal dysfunction. If the creatinine clearance is below 30 molan, then unfractionated hepin is generally the safer choice because it clearance isn't kidney dependent.
Good point. Renal function matters. Any other anti-coagulants?
Fontaranex is another option. It's an indirect factor as a inhibitor. It's also effective and notably it seems to have a lower bleeding incidence compared to an oxiparin in some studies.
Lower bleeding. That's good. Okay. And for antiplatlets, we know ASA is key.
ASA is foundational. Yes. Started promptly, continued longterm. Usually 81 milligram daily long-term after an initial loading dose but it's typically combined with a second antipllet agent
and that's where the P2Y12 inhibitors come in clapitol tagrreller prashugril
exactly clidal was the first big one shown to provide benefit when added to ASA significantly reducing adverse cardiac events
but there's a catch with clapidogil right the genetics
yes that's a key nuance its effectiveness can be diminished in patients who are poor metabolizers due to certain genetic vari in the CYP2C19 enzyme which is needed to activate the drug.
Do we test for that routinely?
No. Routine genetic testing isn't currently recommended across the board, but it's an important factor to consider. If a patient isn't responding as expected or if they have a spent thrombosis despite being on clapadogil
okay so that led to the newer more potent options like prashagil and teagural what makes them different
precisely prugil is more potent than clopedogil but that potency comes with a significantly increased risk of bleeding
more bleeding risk. especially in older patients, those with low body weight or anyone with a prior history of stroke or TIA. It's actually contraindicated in patients with prior stroke IIA. So, its use is generally more restricted, often considered in higher risk patients undergoing PCI, particularly if they're getting a stent and are at high risk for stent thrombosis.
So, careful patient selection for proagril. What about teagur?
Togagler is also more potent than clapadigril and it has an advantage in that it doesn't require metabolic activation. So its onset and offset are faster and perhaps more predictable.
No activation needed,
right? Studies like Plato showed it led to lower rates of cardiovascular death, MI or stroke compared to Clapopil.
That sounds good. Downsides.
It does come with an increase in non-annabi related major bleeding. And a fairly common side effect is dysmia or shortness of breath which can sometimes lead to patients needing to switch therapy.
Dysmia. Okay. Wow, that's a lot of detail on the antiplatlets, but it's clearly critical.
So pulling this together for pharmacists especially for exams any practical therapeutic tips to consolidate this unmi management
absolutely a crucial tip remember that standard long-term ASA dose is 81 milligrams daily get that loading dose right initially but it's 81 milligrams long-term
81 millig daily check
and know those holding times for non-urgent bypass surgery this comes up clapidogeral or dicagular should ideally be held 5 days prior pressure needs even longer 7 days.
5 days for clapigel to coaguler, seven for paragrow. Got it. Why the hold?
To reduce the risk of major bleeding during and after the surgery. That distinction and holding times is really important for patient safety around CBD.
Okay. Very practical. Now, let's shift gears completely to STEMI ST elevation MI. This is truly a medical emergency, isn't it?
Absolutely. Time is critical here. Even more so than NT STEMIs.
Okay. The goals must be even more immediate, more critical.
They are. We're aiming to decrease mortality obviously, but also contain the infar size limit, the amount of heart muscle damage, salvage as much myioardium as possible, and crucially quickly reestablish patency or openness of the infar related artery, get the blood flowing again fast.
And the initial investigations, still history, ECG, traropponin,
yes, but with even more urgency, rapid targeted history, stat ECGs often repeated every 1530 minutes if the first isn't diagnostic, but suspicion is high. And baseline traropponin though treatment decision s for STEMI often can't wait for the tronin result if the ECG is clear
right the ECG changes are key so how do we achieve that rapid reestablishment of blood flow what's the gold standard approach
primary perccutaneous coronary intervention or PCI angoplasty and often stenting that's the preferred firstline therapy for most STEMI patients
PCA but there's a time window right
yes a critical one yeah the goal is to get the patient from first medical contact like paramedics arriving to the device being used in the kath lab in 90 minutes or less.
90 minutes FMCA to device.
Exactly. That's the ideal scenario, especially if they can get to a hospital that does a lot of PCIs.
What if PCI isn't immediately available, say in a more rural setting or if transport takes too long? What's plan B?
Good question. If PCI isn't feasible within about 120 minutes or 2 hours of that first medical contact, then a phiccoin invasive strategy is recommend.
Phicinvasive meaning drugs first.
Yes, it involves giving prompt fibbronolytic therapy clot busting drugs as the first line. approach to open the artery chemically
fibbronolysis and there's a time goal for that too.
Absolutely. The goal is a door to needle time from arrival at the hospital to starting the fibbrronolytic infusion of 30 minutes or less.
30 minutes door to needle
right and it's most effective if it's given within the first few hours ideally within 6 hours of symptom onset. After fibbronolysis patients are typically transferred to a PCI capable center anyway for angography and potential rescue or routine PCI later.
Okay. Okay, that makes sense. Now, are there significant pharmacologic differences in managing STEMI compared to ENT STEMI that our listeners really need to zero in on?
Yes, there are definitely some key distinctions to know
like what?
Well, for anti-coagulation with fibbronolytics, introvenous unfractionated hepin is typically administered. An occipin has shown superiority with some fibbronolytics like tenectto but needs caution in the elderly or those with renal impairment.
Okay, what else? ASA is still key presumably.
Oh, absolutely. ASA is vital. Loading dose then daily continued longterm and maybe consider a PPI alongside it if the patient has a history of GI bleeding.
Right. Beta blockers too.
Yes, beta blockers are still recommended usually started orally within 24 hours once the patient is hemodynamically stable. We titrate to that resting heart rate of 50 60 BPM similar to NTEMI.
Okay, here's where I suspect a big difference lies.
absolutely a crucial tip remember that standard long-term ASA dose is 81 milligrams daily get that loading dose right initially but it's 81 milligrams long-term
81 millig daily check
and know those holding times for non-urgent bypass surgery this comes up clapidogeral or dicagular should ideally be held 5 days prior pressure needs even longer 7 days.
5 days for clapigel to coaguler, seven for paragrow. Got it. Why the hold?
To reduce the risk of major bleeding during and after the surgery. That distinction and holding times is really important for patient safety around CBD.
Okay. Very practical. Now, let's shift gears completely to STEMI ST elevation MI. This is truly a medical emergency, isn't it?
Absolutely. Time is critical here. Even more so than NT STEMIs.
Okay. The goals must be even more immediate, more critical.
They are. We're aiming to decrease mortality obviously, but also contain the infar size limit, the amount of heart muscle damage, salvage as much myioardium as possible, and crucially quickly reestablish patency or openness of the infar related artery, get the blood flowing again fast.
And the initial investigations, still history, ECG, traropponin,
yes, but with even more urgency, rapid targeted history, stat ECGs often repeated every 1530 minutes if the first isn't diagnostic, but suspicion is high. And baseline traropponin though treatment decision s for STEMI often can't wait for the tronin result if the ECG is clear
right the ECG changes are key so how do we achieve that rapid reestablishment of blood flow what's the gold standard approach
primary perccutaneous coronary intervention or PCI angoplasty and often stenting that's the preferred firstline therapy for most STEMI patients
PCA but there's a time window right
yes a critical one yeah the goal is to get the patient from first medical contact like paramedics arriving to the device being used in the kath lab in 90 minutes or less.
90 minutes FMCA to device.
Exactly. That's the ideal scenario, especially if they can get to a hospital that does a lot of PCIs.
What if PCI isn't immediately available, say in a more rural setting or if transport takes too long? What's plan B?
Good question. If PCI isn't feasible within about 120 minutes or 2 hours of that first medical contact, then a phiccoin invasive strategy is recommend.
Phicinvasive meaning drugs first.
Yes, it involves giving prompt fibbronolytic therapy clot busting drugs as the first line. approach to open the artery chemically
fibbronolysis and there's a time goal for that too.
Absolutely. The goal is a door to needle time from arrival at the hospital to starting the fibbrronolytic infusion of 30 minutes or less.
30 minutes door to needle
right and it's most effective if it's given within the first few hours ideally within 6 hours of symptom onset. After fibbronolysis patients are typically transferred to a PCI capable center anyway for angography and potential rescue or routine PCI later.
Okay. Okay, that makes sense. Now, are there significant pharmacologic differences in managing STEMI compared to ENT STEMI that our listeners really need to zero in on?
Yes, there are definitely some key distinctions to know
like what?
Well, for anti-coagulation with fibbronolytics, introvenous unfractionated hepin is typically administered. An occipin has shown superiority with some fibbronolytics like tenectto but needs caution in the elderly or those with renal impairment.
Okay, what else? ASA is still key presumably.
Oh, absolutely. ASA is vital. Loading dose then daily continued longterm and maybe consider a PPI alongside it if the patient has a history of GI bleeding.
Right. Beta blockers too.
Yes, beta blockers are still recommended usually started orally within 24 hours once the patient is hemodynamically stable. We titrate to that resting heart rate of 50 60 BPM similar to NTEMI.
Okay, here's where I suspect a big difference lies.
Calcium channel blockers. You mentioned avoiding one earlier.
Exactly. This is crucial. Unlike you and STEMI, calcium channel blockers are generally not recommended routinely in STEMI.
Not recommended. Why?
Because studies have suggested they might actually increase morbidity and mortality in the post STEMI setting, particularly the short acting ones. They're only used very cautiously, maybe for persistent eskemia after reprofusion or for rate control and atrial fibrillation if beta blockers are absolutely contraindicated and there's no heart failure.
So a very limited role if any. What about nitrates? Are they used differently in STEMI?
Yes, also used more selectively. Not routinely given to every STEMI patient. like they might be for initial and STEMI pain. In STEMI, nitrates are generally reserved for patients with persistent or recurrent eskeeia or if the patient has complications like a large anterior MI, hypertension or signs of heart failure and avoided entirely in suspected right ventricular MI or severe hypotension.
Got it. More selective use of nitrates. How about AC inhibitors in those MRAs you mentioned?
AC inhibitors are routinely recommended post stemi for almost everyone. Ideally started within hours assuming no contraindications. They reduce mortality and remodeling. They can often be continued indefinitely.
So standard of care post STEMI
pretty much ARBs are the alternative for AC intolerant patients especially those with heart failure or LV dysfunction.
And then the mineralid receptor antagonist MAS like spironolactone or epernomanel those are important additions.
Maybe you add those
for patients who already have an LD ejection fraction under 40% and either have symptoms of heart failure or diabetes provided they are already on an ACE inhibitor and a beta blocker.
So specific criteria again,
yes, they've been shown to further reduce mortality in that group, but you absolutely have to monitor potassium levels closely for hyperc calmia,
right? Potassium monitoring is key with MRAS. And one quick clarification, antiplatelets in STEMI if they get fibonolytics.
Ah, good point. For STEMI patients treated with fibbronolysis, clapidogeral loading dose than daily dose is typically admin ministered a presentation along with SK teagriller is generally preferred if primary PCI is the strategy.
Okay. Clap girl with aolytics. Got it. Beyond the acute management, what are some of the common complications we need to keep in mind that can happen after a STEMI?
Yeah. Unfortunately, STEMI can lead to several complications. Things like recurrent eskeeia or reinfarction, heart failure developing or worsening, various arhythmias, both atrial and ventricular
dangerous arhythmia
can be. Yes. Like ventricular tacicardia or fibrillation. And then Y much rare but absolutely devastating are the severe mechanical complications
like what
things like a rupture of the papillary muscle leading to acute mitral regurgitation or a ventricular septile rupture a hole between the ventricles these are surgical emergencies.
Wow. Okay. Definitely things to be aware of. Now this raises an important question. How do we handle ACS in special populations? Pregnancy or breastfeeding comes to mind. That sounds like a unique challenge.
It absolutely is. And while care ACS in pregnancy seems to be increasing slightly. Management must always be collaborative. You need the obstetric team and the cardiovascular specialists working closely together.
Makes sense. What about medications?
Well, some are generally considered safe. ASA clapidal is usually the preferred P2Y12 inhibitor if needed. Unfractionated hepin, low molecular weight hepin, beta blockers, and nitrates can generally be used.
Okay. What's contraindicated?
Critically, ACE inhibitors, ARBs, and statins are all contraindicated due to to the risk of harm to the fetus. Terraogenicity,
ACEs, ARBs, statins out in pregnancy. What about reprofusion for STEM?
Exactly. This is crucial. Unlike you and STEMI, calcium channel blockers are generally not recommended routinely in STEMI.
Not recommended. Why?
Because studies have suggested they might actually increase morbidity and mortality in the post STEMI setting, particularly the short acting ones. They're only used very cautiously, maybe for persistent eskemia after reprofusion or for rate control and atrial fibrillation if beta blockers are absolutely contraindicated and there's no heart failure.
So a very limited role if any. What about nitrates? Are they used differently in STEMI?
Yes, also used more selectively. Not routinely given to every STEMI patient. like they might be for initial and STEMI pain. In STEMI, nitrates are generally reserved for patients with persistent or recurrent eskeeia or if the patient has complications like a large anterior MI, hypertension or signs of heart failure and avoided entirely in suspected right ventricular MI or severe hypotension.
Got it. More selective use of nitrates. How about AC inhibitors in those MRAs you mentioned?
AC inhibitors are routinely recommended post stemi for almost everyone. Ideally started within hours assuming no contraindications. They reduce mortality and remodeling. They can often be continued indefinitely.
So standard of care post STEMI
pretty much ARBs are the alternative for AC intolerant patients especially those with heart failure or LV dysfunction.
And then the mineralid receptor antagonist MAS like spironolactone or epernomanel those are important additions.
Maybe you add those
for patients who already have an LD ejection fraction under 40% and either have symptoms of heart failure or diabetes provided they are already on an ACE inhibitor and a beta blocker.
So specific criteria again,
yes, they've been shown to further reduce mortality in that group, but you absolutely have to monitor potassium levels closely for hyperc calmia,
right? Potassium monitoring is key with MRAS. And one quick clarification, antiplatelets in STEMI if they get fibonolytics.
Ah, good point. For STEMI patients treated with fibbronolysis, clapidogeral loading dose than daily dose is typically admin ministered a presentation along with SK teagriller is generally preferred if primary PCI is the strategy.
Okay. Clap girl with aolytics. Got it. Beyond the acute management, what are some of the common complications we need to keep in mind that can happen after a STEMI?
Yeah. Unfortunately, STEMI can lead to several complications. Things like recurrent eskeeia or reinfarction, heart failure developing or worsening, various arhythmias, both atrial and ventricular
dangerous arhythmia
can be. Yes. Like ventricular tacicardia or fibrillation. And then Y much rare but absolutely devastating are the severe mechanical complications
like what
things like a rupture of the papillary muscle leading to acute mitral regurgitation or a ventricular septile rupture a hole between the ventricles these are surgical emergencies.
Wow. Okay. Definitely things to be aware of. Now this raises an important question. How do we handle ACS in special populations? Pregnancy or breastfeeding comes to mind. That sounds like a unique challenge.
It absolutely is. And while care ACS in pregnancy seems to be increasing slightly. Management must always be collaborative. You need the obstetric team and the cardiovascular specialists working closely together.
Makes sense. What about medications?
Well, some are generally considered safe. ASA clapidal is usually the preferred P2Y12 inhibitor if needed. Unfractionated hepin, low molecular weight hepin, beta blockers, and nitrates can generally be used.
Okay. What's contraindicated?
Critically, ACE inhibitors, ARBs, and statins are all contraindicated due to to the risk of harm to the fetus. Terraogenicity,
ACEs, ARBs, statins out in pregnancy. What about reprofusion for STEM?
Primary PCI is definitely the preferred treatment for STEMI during pregnancy as it avoids the systemic effects of fibonolytics. Litics might be considered as an alternative only if PCI isn't readily available and the maternal benefit outweighs potential risks.
Okay. PCI preferred. And for breastfeeding mothers, similar considerations.
For breastfeeding mothers, the workup for ACS shouldn't be delayed. Medication wise, ASA, UFH, LMW and most beta blockers are generally considered safe
safe for breastfeeding
generally. Yes. However, data is limited for many other cardiovascular meds used in ACS like some antiplatlets or ACE inhibitors. So sometimes discontinuing breastfeeding might be necessary to prioritize the mother's treatment and health outcomes. It always a careful riskbenefit discussion with the patient.
A very complex situation. This has been incredibly detailed and practical. To maybe summarize some overarching therapeutic tips for our PBC candidates. What are the absolute musters from all this?
Okay, let's boil it down. Beyond those critical time goals, door to needle, A30 men for luittics, FMC to device AD men for primary PCI, remember specific scenarios like for right ventricular infarks, avoid nitrates and diuretics, use fluids, maybe inotropes to treat hypotension instead.
Right ventricle, no nitro. Got it.
Also, consistent early administration ideally within 24 for hours of beta blockers and ECE inhibitors postMI is crucial. Titrate them carefully.
Early beta blockers and ACEs.
Yes. And a practical tip for patient comfort, especially right after the MI, consider stool softeners to prevent straining which can stress the heart and maybe short-term anxolytics if needed for significant immediate postMI anxiety.
Good practical points.
Finally, and this may be the most important study tip, really know your algorithms like figure one for you on STEMI and figure two for STEMI and the references and become familiar with a comprehensive tables like table two covering dosages, side effects, interactions. They're invaluable resources for pulling it all together for exams and practice.
Fantastic summary. We've covered a huge amount today really from diagnosing ACS, navigating those complex therapeutic choices for both N STEMI and STEMI and even touching on critical special considerations like pregnancy. This deep dive hopefully gave you the most important nuggets from the therapeutic choices chapter, helping you feel genuinely well informed and uh maybe a bit more confident. Hope so.
So, here's a thought for you, the listener, to mull over. How does really understanding these specific drug interactions like we discussed with nitrates and PTE5 inhibitors or the nuances between antiplatlets? How does that knowledge directly translate into preventing real harm, preventing adverse outcomes in a busy everyday pharmacy setting? It's more than just memorizing facts for an exam, isn't it? It
really is. It's about patient safety.
Remember, this deep dive was brought to you by the Pharma Board Group based on the CTC reference. Okay, before we wrap up, here's a quick multiple choice question to test your knowledge based on our discussion. Based on our discussion regarding the management of acute coronary syndromes, which of the following medications is a contraindication for the use of nitrates in patients with unstable angina or nmi? Is it a metiprol, b selenophil, c clopidigrol, or d aspirin? Take a moment to think about it. Which one should make you stop and say hold on no nitrates? The answer of course is B selenaphil. Due to that at risk of significant potentially life-threatening hypotension. Remember, nitrate should not be used if selenaphil or vardmophil were taken within the previous 24 hours or tadalapil within the previous 48 hours.
Absolutely crucial point to remember. Keep diving deeper into your studies everyone. That critical thinking, that precise application of this knowledge, it will serve you exceptionally well both in your exams and more importantly in your future practice.
Okay. PCI preferred. And for breastfeeding mothers, similar considerations.
For breastfeeding mothers, the workup for ACS shouldn't be delayed. Medication wise, ASA, UFH, LMW and most beta blockers are generally considered safe
safe for breastfeeding
generally. Yes. However, data is limited for many other cardiovascular meds used in ACS like some antiplatlets or ACE inhibitors. So sometimes discontinuing breastfeeding might be necessary to prioritize the mother's treatment and health outcomes. It always a careful riskbenefit discussion with the patient.
A very complex situation. This has been incredibly detailed and practical. To maybe summarize some overarching therapeutic tips for our PBC candidates. What are the absolute musters from all this?
Okay, let's boil it down. Beyond those critical time goals, door to needle, A30 men for luittics, FMC to device AD men for primary PCI, remember specific scenarios like for right ventricular infarks, avoid nitrates and diuretics, use fluids, maybe inotropes to treat hypotension instead.
Right ventricle, no nitro. Got it.
Also, consistent early administration ideally within 24 for hours of beta blockers and ECE inhibitors postMI is crucial. Titrate them carefully.
Early beta blockers and ACEs.
Yes. And a practical tip for patient comfort, especially right after the MI, consider stool softeners to prevent straining which can stress the heart and maybe short-term anxolytics if needed for significant immediate postMI anxiety.
Good practical points.
Finally, and this may be the most important study tip, really know your algorithms like figure one for you on STEMI and figure two for STEMI and the references and become familiar with a comprehensive tables like table two covering dosages, side effects, interactions. They're invaluable resources for pulling it all together for exams and practice.
Fantastic summary. We've covered a huge amount today really from diagnosing ACS, navigating those complex therapeutic choices for both N STEMI and STEMI and even touching on critical special considerations like pregnancy. This deep dive hopefully gave you the most important nuggets from the therapeutic choices chapter, helping you feel genuinely well informed and uh maybe a bit more confident. Hope so.
So, here's a thought for you, the listener, to mull over. How does really understanding these specific drug interactions like we discussed with nitrates and PTE5 inhibitors or the nuances between antiplatlets? How does that knowledge directly translate into preventing real harm, preventing adverse outcomes in a busy everyday pharmacy setting? It's more than just memorizing facts for an exam, isn't it? It
really is. It's about patient safety.
Remember, this deep dive was brought to you by the Pharma Board Group based on the CTC reference. Okay, before we wrap up, here's a quick multiple choice question to test your knowledge based on our discussion. Based on our discussion regarding the management of acute coronary syndromes, which of the following medications is a contraindication for the use of nitrates in patients with unstable angina or nmi? Is it a metiprol, b selenophil, c clopidigrol, or d aspirin? Take a moment to think about it. Which one should make you stop and say hold on no nitrates? The answer of course is B selenaphil. Due to that at risk of significant potentially life-threatening hypotension. Remember, nitrate should not be used if selenaphil or vardmophil were taken within the previous 24 hours or tadalapil within the previous 48 hours.
Absolutely crucial point to remember. Keep diving deeper into your studies everyone. That critical thinking, that precise application of this knowledge, it will serve you exceptionally well both in your exams and more importantly in your future practice.
نارسایی قلبی
Welcome to the deep dive. We focus on cutting through the noise to give you those critical actionable insights. And today, well, this one's specifically for you, our Canadian pharmacist PBC candidates. We really get the challenge you're facing, mastering complex topics like heart failure for your boards. Our mission today, honestly, it's about providing some peace of mind. We want to make sure you don't miss anything absolutely crucial for the exam and, you know, just as vital for your confidence when you're actually practicing. So, yeah. Today we're diving deep into heart failure. We're pulling out the essential bits from that key chapter in your text, therapeutic choices, medication algorithms, those really important tables, and uh practical tips that actually make a difference. This isn't just a summary. Think of it as a curated session.
That's exactly right. And just so you know where this is coming from, this deep dive is brought to you by the Pharma board group. It's specifically based on the therapeutic choices reference, the CTC. So you can be confident the information is solid and well directly relevant.
Absolely. Absolutely. And look, we know many of you might not be native English speakers, so we're going to keep the pace clear, easy to follow. We want every detail to really uh land properly. So, let's unpack this important topic together, taking our time. Okay. So, every patient walking into the pharmacy is, you know, a unique puzzle, but when it comes to heart failure, just understanding what it is, not just a diagnosis, but like a dynamic syndrome, that seems like the right place to start our deep dive. How do we first think about heart failure? or HF.
That's a great starting point. Yeah, HF isn't just one disease. It's um a complex clinical syndrome. Picture a patient coming in with say shortness of breath, that's dispa, maybe some fluid retention like swollen ankles, maybe a cough, and just feeling tired all the time. What makes it heart failure is when those symptoms line up with actual structural or functional heart disease. And that's often backed up by uh highriotic peptide levels or clear signs of congestion.
Right? So, it's a syndrome, a whole collection of things, not just one neat label. What's the bigger picture then for us as future pharmacists?
What's really important to grasp is how dynamic it is, how it progresses. Patients might feel stable for a while, but HF symptoms can definitely fluctuate. And even with all the advances we've made, its prevalence is actually increasing globally, mostly because populations are getting older. This makes it a huge contributor to well, morbidity, mortality, and health care costs. Just to give you an idea, annual mortality rates can range anywhere from 6% to maybe 25%. It really underscores how serious this is.
Wow. 6 to 25%. That definitely puts the impact into perspective. Yeah. Okay. Let's talk classification because, you know, for a pharmacist looking at a patient's chart trying to figure out the treatment plan, that lift ventricular ejection fraction, LVEF, that's kind of the hinge point, isn't it?
It absolutely is. LVEF is how we often sort HF patients and it really guides a lot of our therapy choices.
So, let's walk through those main types. Maybe starting with the one we've uh traditionally focused on most.
Sure. First up is heart failure with reduced ejection fraction. or HFR EF. That's defined as an LVF of 40% or less.
Basically, the heart's pump function is down and the left ventricle is often bigger, dilated. Historically, about half of HF cases fall into this bucket. And yeah, most of the big clinical trials were done in this group.
Okay. HFREF, LVF less than or equal to 40. Got it. And then there's the other side of the coin where the LVF looks well relatively normal.
Exactly. That's heart failure with preserved ejection fraction or HFPF. Here the LVF is 50% or higher. The problem isn't so much the pumping out but rather how the heart relaxes and fills its abnormal myioardial relaxation.
Welcome to the deep dive. We focus on cutting through the noise to give you those critical actionable insights. And today, well, this one's specifically for you, our Canadian pharmacist PBC candidates. We really get the challenge you're facing, mastering complex topics like heart failure for your boards. Our mission today, honestly, it's about providing some peace of mind. We want to make sure you don't miss anything absolutely crucial for the exam and, you know, just as vital for your confidence when you're actually practicing. So, yeah. Today we're diving deep into heart failure. We're pulling out the essential bits from that key chapter in your text, therapeutic choices, medication algorithms, those really important tables, and uh practical tips that actually make a difference. This isn't just a summary. Think of it as a curated session.
That's exactly right. And just so you know where this is coming from, this deep dive is brought to you by the Pharma board group. It's specifically based on the therapeutic choices reference, the CTC. So you can be confident the information is solid and well directly relevant.
Absolely. Absolutely. And look, we know many of you might not be native English speakers, so we're going to keep the pace clear, easy to follow. We want every detail to really uh land properly. So, let's unpack this important topic together, taking our time. Okay. So, every patient walking into the pharmacy is, you know, a unique puzzle, but when it comes to heart failure, just understanding what it is, not just a diagnosis, but like a dynamic syndrome, that seems like the right place to start our deep dive. How do we first think about heart failure? or HF.
That's a great starting point. Yeah, HF isn't just one disease. It's um a complex clinical syndrome. Picture a patient coming in with say shortness of breath, that's dispa, maybe some fluid retention like swollen ankles, maybe a cough, and just feeling tired all the time. What makes it heart failure is when those symptoms line up with actual structural or functional heart disease. And that's often backed up by uh highriotic peptide levels or clear signs of congestion.
Right? So, it's a syndrome, a whole collection of things, not just one neat label. What's the bigger picture then for us as future pharmacists?
What's really important to grasp is how dynamic it is, how it progresses. Patients might feel stable for a while, but HF symptoms can definitely fluctuate. And even with all the advances we've made, its prevalence is actually increasing globally, mostly because populations are getting older. This makes it a huge contributor to well, morbidity, mortality, and health care costs. Just to give you an idea, annual mortality rates can range anywhere from 6% to maybe 25%. It really underscores how serious this is.
Wow. 6 to 25%. That definitely puts the impact into perspective. Yeah. Okay. Let's talk classification because, you know, for a pharmacist looking at a patient's chart trying to figure out the treatment plan, that lift ventricular ejection fraction, LVEF, that's kind of the hinge point, isn't it?
It absolutely is. LVEF is how we often sort HF patients and it really guides a lot of our therapy choices.
So, let's walk through those main types. Maybe starting with the one we've uh traditionally focused on most.
Sure. First up is heart failure with reduced ejection fraction. or HFR EF. That's defined as an LVF of 40% or less.
Basically, the heart's pump function is down and the left ventricle is often bigger, dilated. Historically, about half of HF cases fall into this bucket. And yeah, most of the big clinical trials were done in this group.
Okay. HFREF, LVF less than or equal to 40. Got it. And then there's the other side of the coin where the LVF looks well relatively normal.
Exactly. That's heart failure with preserved ejection fraction or HFPF. Here the LVF is 50% or higher. The problem isn't so much the pumping out but rather how the heart relaxes and fills its abnormal myioardial relaxation.
The left ventricle isn't dilated and you might see things like concentric remodeling or a bigger left atrium. HFPF uh tends to affect older patients, more women and folks with obesity, hypertension, aphib, sleep apnea, diabetes. Diagnosing it can be trickier which, you know, makes managing it tough too.
And there's those newer classifications popping up too, right? Just briefly.
Yeah. But briefly, there's HF with mildly reduced ejection fraction or HFMEF, that's LVEF between 41 and 49%. And then HF with improved ejection fraction, HFMPF, that's for patients who started with HFREF, but then their LVF got significantly better. These just show how HF can change over time.
Okay, so we have the definitions down, but when a patient is actually in front of you or you're looking at their profile, what are those specific red flags, maybe beyond just general fatigue or swelling that really scream heart failure to a pharmacist and What common things should we watch out for that could actually make their HF worse?
That's super important for assessment. Beyond the usual signs, look for more specific things like uh bendopnia, that's getting short of breath, just bending over, or an elevated jugular venus pressure, JVP, which signals fluid overload. A third heart sound, S3, that's a classic sign, too. Now, for the pharmacist eye, table four in your reference, it's not just a list. It's like your early warning system. It points out things that can make HF worse. Non-adherence to meds or diet. Huge. infections absolutely and critically certain drugs. We're talking medications that cause sodium and fluid retention like NSAIDs, thazolid, adion also negative inotropes. Think non- dihydropiritine calcium channel blockers like deltasm, verapamel, and most antiarithmics. Recognizing these can honestly be the difference between stability and an ER visit.
Okay, so we suspect HF based on those signs and maybe potential triggers. How do we actually confirm it? What are the really crucial first tests that nail down the diagnosis? Right. So, while a good history, physical exam, and standard labs are all foundational, the echo cardiogram is absolutely essential for all patients with suspected heart failure. It's the key test. It shows ventricular size, how well it's pumping the LVF, and checks the heart valves. Without it, you're really just guessing.
And what about those naturic peptide tests like BNP or NT Probnp? Where do they fit in?
These tests, you'll see them in table 5. They're incredibly useful, especially if the diagnosis isn't totally clear. They help us rule pull in or rule out HF. For example, a BNP below 100 PGML makes HF pretty unlikely. But if it's over 400 PGML, then HF is very likely. Those cut offs are handy to remember.
All right, so we've got a clearer picture of what HF is and how it's diagnosed. But let's pivot now to the why. When we're managing a patient with heart failure, what are the big goals driving every decision we make about their treatment?
Ultimately, the goals are kind of twofold. First, and this is critical, we want to reduce mortality, keep people alive longer, and reduce morbidity, which really means preventing those awful HF hospitalizations and flare-ups. Second, and just as important for their day-to-day life, is improving their symptoms, helping them be more active, boosting their exercise tolerance, and just generally improving their quality of life. It's about quality, not just quantity.
And as pharmacists, even before we jump to the meds, what are those foundational non-drug strategies we should be talking to patients about?
These are absolutely the bedrock. Patients need to manage other conditions. CAD diabetes, high blood pressure. They have to avoid those trigger factors we mentioned from table four. Lifestyle is huge. Moderate regular activity if they're stable, strict sodium limits like less than 2 to three grams a day and limited alcohol max one drink a day or none at all if it's alcoholic cardiammyopathy. And something really specific you should advise daily weight monitoring.
And there's those newer classifications popping up too, right? Just briefly.
Yeah. But briefly, there's HF with mildly reduced ejection fraction or HFMEF, that's LVEF between 41 and 49%. And then HF with improved ejection fraction, HFMPF, that's for patients who started with HFREF, but then their LVF got significantly better. These just show how HF can change over time.
Okay, so we have the definitions down, but when a patient is actually in front of you or you're looking at their profile, what are those specific red flags, maybe beyond just general fatigue or swelling that really scream heart failure to a pharmacist and What common things should we watch out for that could actually make their HF worse?
That's super important for assessment. Beyond the usual signs, look for more specific things like uh bendopnia, that's getting short of breath, just bending over, or an elevated jugular venus pressure, JVP, which signals fluid overload. A third heart sound, S3, that's a classic sign, too. Now, for the pharmacist eye, table four in your reference, it's not just a list. It's like your early warning system. It points out things that can make HF worse. Non-adherence to meds or diet. Huge. infections absolutely and critically certain drugs. We're talking medications that cause sodium and fluid retention like NSAIDs, thazolid, adion also negative inotropes. Think non- dihydropiritine calcium channel blockers like deltasm, verapamel, and most antiarithmics. Recognizing these can honestly be the difference between stability and an ER visit.
Okay, so we suspect HF based on those signs and maybe potential triggers. How do we actually confirm it? What are the really crucial first tests that nail down the diagnosis? Right. So, while a good history, physical exam, and standard labs are all foundational, the echo cardiogram is absolutely essential for all patients with suspected heart failure. It's the key test. It shows ventricular size, how well it's pumping the LVF, and checks the heart valves. Without it, you're really just guessing.
And what about those naturic peptide tests like BNP or NT Probnp? Where do they fit in?
These tests, you'll see them in table 5. They're incredibly useful, especially if the diagnosis isn't totally clear. They help us rule pull in or rule out HF. For example, a BNP below 100 PGML makes HF pretty unlikely. But if it's over 400 PGML, then HF is very likely. Those cut offs are handy to remember.
All right, so we've got a clearer picture of what HF is and how it's diagnosed. But let's pivot now to the why. When we're managing a patient with heart failure, what are the big goals driving every decision we make about their treatment?
Ultimately, the goals are kind of twofold. First, and this is critical, we want to reduce mortality, keep people alive longer, and reduce morbidity, which really means preventing those awful HF hospitalizations and flare-ups. Second, and just as important for their day-to-day life, is improving their symptoms, helping them be more active, boosting their exercise tolerance, and just generally improving their quality of life. It's about quality, not just quantity.
And as pharmacists, even before we jump to the meds, what are those foundational non-drug strategies we should be talking to patients about?
These are absolutely the bedrock. Patients need to manage other conditions. CAD diabetes, high blood pressure. They have to avoid those trigger factors we mentioned from table four. Lifestyle is huge. Moderate regular activity if they're stable, strict sodium limits like less than 2 to three grams a day and limited alcohol max one drink a day or none at all if it's alcoholic cardiammyopathy. And something really specific you should advise daily weight monitoring.
Tell patients, call us or your doctor if you gain half a kilogram a day for a few days straight or 2 kg in just 3 days. That's often the very first sign of fluid building up.
Oh, and keeping up with vaccinations, flu, numaccoal, COVID, that's really recommended, too.
Those non-drug steps are clearly vital. But sometimes patients need more help. Before we get into the powerhouse medications, what advanced tools might come into play for more severe cases?
Yeah, for more advanced situations, we start thinking about device therapies. Things like implantable cardioverter defibrillators, ICDs, or cardiac recynchronization therapy, CRT. Sometimes even left ventricular assistant devices, LVADs, and then there are surgical options like revascularization or even heart transplantation for specific patients. These definitely pave the way for the medications which are often the main pillar of therapy. And what's really interesting now and it's a big shift in the guidelines is this push for early initiation of quadruple therapy. It's the new standard really for managing HFREF. It means starting four key drug classes pretty much right away.
Okay, quadruple therapy. So the goal then is to start all four. That's an AR NI or an ECE inhibitor or an ARB plus a beta blocker plus an MRA plus an SGLT2 inhibitor and then carefully titrate them up to the target dose or whatever the patient can tolerate ideally within what 3 to 6 months. But you said there's no prescribed order for starting them feels flexible but maybe a bit daunting. How do we as pharmacists decide where to begin if there isn't a set ABC? What's your insight there?
That really comes down to clinical judgment. While there's no strict order, you look at the patient in front of you. What are their symptoms? like right now, what's their blood pressure, renal function,
potassium level? So, for instance, if someone's really congested, you might adjust their diuretic first, maybe alongside starting an ACI or ARNI to manage volume. If their heart rate's high and blood pressure allows it, maybe a beta blocker is a good early step. The key is to get something from each class going as soon as you can and then systematically work on optimizing. Don't feel like you have to max out one drug before starting the next.
Okay, let's dive into each of these. core classes focusing on the practical stuff you need to know starting with a inhibitors and ARBs
right their role seems clear in improving symptoms cutting down hospitalizations MIS death but what are the key monitoring points for pharmacists what do we really need to watch vigilance is definitely key you need to check their serum creatinine potassium and blood pressure usually about 7 to 14 days after starting or changing the dose and here is a critical point for exams and practice it's nor normal, even expected to see serum creatinin go up by maybe 30%. That's generally okay. The main risks you're watching for are hypercalemia, hypothacium, and anodema, that's swelling. Be extra aware that angodma is more common in patients who identify as black, those with a history of drug rash or older folks. If someone gets that ACE inhibitor cough or angiodma, ARBs like candaceartin or sartin are good alternatives, but still keep an eye out for angodma even though it's less common with ARBs. Okay, next up, the AI. Right now, that's the basartin. vitrol combo on tresto.
Yeah, that mechanism is different and the big paradigm jackf trial showed it was better than an elilapal for reducing CV death and HF hospitalizations, but you mentioned a mandatory 36-hour wash out when switching from an AC inhibitor. That sounds critical. Have you seen problems when that's missed? What's the real risk?
Oh, it's absolutely critical. And yes, problems definitely happen if that wash out is skipped. The risk is a significantly higher chance of angiodma. Those 36 hours are non-negotiable. Really, another key point, if a patient's on an ARNI regular BMP levels aren't useful anymore.
Oh, and keeping up with vaccinations, flu, numaccoal, COVID, that's really recommended, too.
Those non-drug steps are clearly vital. But sometimes patients need more help. Before we get into the powerhouse medications, what advanced tools might come into play for more severe cases?
Yeah, for more advanced situations, we start thinking about device therapies. Things like implantable cardioverter defibrillators, ICDs, or cardiac recynchronization therapy, CRT. Sometimes even left ventricular assistant devices, LVADs, and then there are surgical options like revascularization or even heart transplantation for specific patients. These definitely pave the way for the medications which are often the main pillar of therapy. And what's really interesting now and it's a big shift in the guidelines is this push for early initiation of quadruple therapy. It's the new standard really for managing HFREF. It means starting four key drug classes pretty much right away.
Okay, quadruple therapy. So the goal then is to start all four. That's an AR NI or an ECE inhibitor or an ARB plus a beta blocker plus an MRA plus an SGLT2 inhibitor and then carefully titrate them up to the target dose or whatever the patient can tolerate ideally within what 3 to 6 months. But you said there's no prescribed order for starting them feels flexible but maybe a bit daunting. How do we as pharmacists decide where to begin if there isn't a set ABC? What's your insight there?
That really comes down to clinical judgment. While there's no strict order, you look at the patient in front of you. What are their symptoms? like right now, what's their blood pressure, renal function,
potassium level? So, for instance, if someone's really congested, you might adjust their diuretic first, maybe alongside starting an ACI or ARNI to manage volume. If their heart rate's high and blood pressure allows it, maybe a beta blocker is a good early step. The key is to get something from each class going as soon as you can and then systematically work on optimizing. Don't feel like you have to max out one drug before starting the next.
Okay, let's dive into each of these. core classes focusing on the practical stuff you need to know starting with a inhibitors and ARBs
right their role seems clear in improving symptoms cutting down hospitalizations MIS death but what are the key monitoring points for pharmacists what do we really need to watch vigilance is definitely key you need to check their serum creatinine potassium and blood pressure usually about 7 to 14 days after starting or changing the dose and here is a critical point for exams and practice it's nor normal, even expected to see serum creatinin go up by maybe 30%. That's generally okay. The main risks you're watching for are hypercalemia, hypothacium, and anodema, that's swelling. Be extra aware that angodma is more common in patients who identify as black, those with a history of drug rash or older folks. If someone gets that ACE inhibitor cough or angiodma, ARBs like candaceartin or sartin are good alternatives, but still keep an eye out for angodma even though it's less common with ARBs. Okay, next up, the AI. Right now, that's the basartin. vitrol combo on tresto.
Yeah, that mechanism is different and the big paradigm jackf trial showed it was better than an elilapal for reducing CV death and HF hospitalizations, but you mentioned a mandatory 36-hour wash out when switching from an AC inhibitor. That sounds critical. Have you seen problems when that's missed? What's the real risk?
Oh, it's absolutely critical. And yes, problems definitely happen if that wash out is skipped. The risk is a significantly higher chance of angiodma. Those 36 hours are non-negotiable. Really, another key point, if a patient's on an ARNI regular BMP levels aren't useful anymore.
The sacubital part blocks neprolin which breaks down BMP but NT probnp is fine as still a good marker. Also watch for potential hypotension AR and can lower blood pressure quite a bit. So you might need to adjust diuretic doses and titrate AR and every 2 to 4 weeks. All right moving to beta blockers.
These are obviously huge in HFREF cutting hospitalizations and mortality. Bisoprolol and carvidol are the ones specifically shown to reduce mortality, right?
Exactly. When you start beta blockers, always start very low and titrate up slowly, like every 2 to 4 weeks. This is vital because, and this is a really critical point for your exam and practice, beta blockers should not be started or have their dose increased when a patient is acutely decompensated.
That's such a key distinction. It sometimes feels a bit counterintuitive, maybe since they're so important long term. Can you elaborate just a bit on why starting them during acute decompensation is a no-go?
That's a great question. It really highlights the nuances. So in acute decompensation, the heart's already struggling, right? Beta blockers acutely they reduce heart contractility and heart rate. If you give them, right, then you can actually worsen cardiac output, potentially leading to um severe hemodynamic instability or even cardiogenic shock. We use them for their long-term benefits on heart remodeling, but the patient needs to be stable for that. As pharmacists, you'll monitor blood pressure, heart rate, look for signs of worsening HF. Daily weights are crucial here, and counsel patients. You might feel a bit worse temporar arily when starting or increasing the dose but stick with it the long-term benefits are substantial
then we have the mineral corticoid receptor antagonists or MAS sperolactone epinent rune
yeah they play a big role in HFRF too reducing mortality and morbidity but what are the absolute must know contraindications or monitoring points here
they definitely come with some big warnings mostly around potassium and kidney function you absolutely do not use them if baseline potassium is over 5 millmal or if their creatinine clearance is under 30 mil a minute. Monitoring serum creatinine and potassium is crucial usually at 3 days 7 days after starting or changing dose then monthly for 3 months and then maybe every 3 months once they're stable. And a practical tip if a patient gets gynecomastia breasted enlargement with spironolactone which can happen because of its anti-androgen effects. Eperone is a great alternative. It doesn't have that side effect. And then the relatively newer but really impactful class SGLT2 inhibitors daglyloin and propololis. expert. So, what's the big deal with this class in heart failure? Their impact on reducing bad outcomes has been huge, and this is key. It works whether or not the patient has diabetes.
This has been truly groundbreaking. These are now considered for basically all HFREF patients, unless there's a specific reason not to use them. You do need to be aware they can cause some volume depletion. It's a mild diuretic effect, so you might even need to lower other diuretic doses. Also, expect an initial dip in their EGFR maybe in the first four weeks. That's generally okay if it's less than about 15%. This is a really powerful class every pharmacist needs to be comfortable with for HFREF. Now,
okay, let's quickly touch on a few other important agents for HFREF that aren't part of that core four. First, ivabberdine,
right? Ivdine has a pretty specific uh niche role. It's for patients with an LVEF of 35% or less and a resting heart rate of 77 BPM or more despite being on the best possible beta blocker dose or if they just can't tolerate beta blockers. Very important point. Do not use it if the patient has atrial fibrillation. It only works on the finest node.
Got it. Next. Dyoxin, an older drug in the HF world.
Yeah, dyoxin. It helps with symptoms and reduces hospitalizations, but it's crucial to remember it does not reduce mortality.
These are obviously huge in HFREF cutting hospitalizations and mortality. Bisoprolol and carvidol are the ones specifically shown to reduce mortality, right?
Exactly. When you start beta blockers, always start very low and titrate up slowly, like every 2 to 4 weeks. This is vital because, and this is a really critical point for your exam and practice, beta blockers should not be started or have their dose increased when a patient is acutely decompensated.
That's such a key distinction. It sometimes feels a bit counterintuitive, maybe since they're so important long term. Can you elaborate just a bit on why starting them during acute decompensation is a no-go?
That's a great question. It really highlights the nuances. So in acute decompensation, the heart's already struggling, right? Beta blockers acutely they reduce heart contractility and heart rate. If you give them, right, then you can actually worsen cardiac output, potentially leading to um severe hemodynamic instability or even cardiogenic shock. We use them for their long-term benefits on heart remodeling, but the patient needs to be stable for that. As pharmacists, you'll monitor blood pressure, heart rate, look for signs of worsening HF. Daily weights are crucial here, and counsel patients. You might feel a bit worse temporar arily when starting or increasing the dose but stick with it the long-term benefits are substantial
then we have the mineral corticoid receptor antagonists or MAS sperolactone epinent rune
yeah they play a big role in HFRF too reducing mortality and morbidity but what are the absolute must know contraindications or monitoring points here
they definitely come with some big warnings mostly around potassium and kidney function you absolutely do not use them if baseline potassium is over 5 millmal or if their creatinine clearance is under 30 mil a minute. Monitoring serum creatinine and potassium is crucial usually at 3 days 7 days after starting or changing dose then monthly for 3 months and then maybe every 3 months once they're stable. And a practical tip if a patient gets gynecomastia breasted enlargement with spironolactone which can happen because of its anti-androgen effects. Eperone is a great alternative. It doesn't have that side effect. And then the relatively newer but really impactful class SGLT2 inhibitors daglyloin and propololis. expert. So, what's the big deal with this class in heart failure? Their impact on reducing bad outcomes has been huge, and this is key. It works whether or not the patient has diabetes.
This has been truly groundbreaking. These are now considered for basically all HFREF patients, unless there's a specific reason not to use them. You do need to be aware they can cause some volume depletion. It's a mild diuretic effect, so you might even need to lower other diuretic doses. Also, expect an initial dip in their EGFR maybe in the first four weeks. That's generally okay if it's less than about 15%. This is a really powerful class every pharmacist needs to be comfortable with for HFREF. Now,
okay, let's quickly touch on a few other important agents for HFREF that aren't part of that core four. First, ivabberdine,
right? Ivdine has a pretty specific uh niche role. It's for patients with an LVEF of 35% or less and a resting heart rate of 77 BPM or more despite being on the best possible beta blocker dose or if they just can't tolerate beta blockers. Very important point. Do not use it if the patient has atrial fibrillation. It only works on the finest node.
Got it. Next. Dyoxin, an older drug in the HF world.
Yeah, dyoxin. It helps with symptoms and reduces hospitalizations, but it's crucial to remember it does not reduce mortality.
It also has a narrow therapeutic window, meaning the difference between a helpful dose and a toxic dose is small. So, you have to carefully monitor serum levels, aiming for that 6 to 1.2 non-mole range to avoid toxicity.
And the combination of nitrates and hydrolysine,
that combo has a specific place. It's useful for patients who can't tolerate ACE inhibitors, ARBs, or ARNIs, maybe because of kidney problems or high potassium. It's also used as an add-on therapy, particularly in black patients, where studies have shown a specific benefit.
Lastly, 5V iron replacement. This one sometimes surprises people.
It's really important for HFREF patients who are iron deficient, and this is key whether they have anemia or not. Studies show IV iron improves their exercise ability, quality of life, and cuts down hospitalizations. And another key point. Oral iron isn't recommended for this specific reason in heart failure. It just doesn't seem to be absorbed or used effectively in the same way.
Expert, just to wrap up HFREF, what's on the pharmacist's danger zone list? Which drugs should we really avoid or use with extreme caution in these patients?
Knowing what to avoid is just as important. Generally, avoid non-dihydropodine calcium channel blockers dilazasmapl because they can weaken the heart's contraction negative inotropic effects. Most Antiarythmics are also generally not recommended except maybe amodderone for very specific reasons as they don't reduce mortality. Statins are a bit different. If a patient is already on one for coronary artery disease, you generally continue it, but you wouldn't start a statin just for the heart failure itself.
Okay, let's shift gears now to heart failure with preserved ejection fraction or HFPF. You mentioned earlier the treatment landscape here has historically been well pretty challenging.
Yeah, traditionally treating HFTPF was mostly about managing the underlying conditions. hypertension, diabetes, aphib controlling fluid volume and trying to improve quality of life. The big challenge was finding drugs that actually reduced mortality unlike the clear wins we saw in HFREF.
But you hinted that this is where things are really starting to change. What's the big news in HFPF treatment?
This is really exciting actually. The SGLT2 inhibitors specifically in pagaloploin are the only drug class right now that has definitively shown improvement in HFPF in the large trials. They mainly work by reducing heartfield your hospitalizations. That's a huge step forward. Also, MRAs like spironolactone should definitely be considered for symptomatic HFPF patients as long as their potassium and kidney function, EGFR, are okay.
Now, let's tackle a really complex highstakes area. Heart failure during pregnancy and breastfeeding. It sounds like it needs very careful navigation.
Oh, absolutely. It's like walking a tight rope. Pregnancy itself puts a lot of strain on the cardiovascular system, which is risky for someone with existing heart failure. We have to constantly balance the mom heart health needs against the potential risks to the baby because yeah a lot of standard HF meds are territogenic. So during pregnancy itself several drugs are definite no-go. ACC inhibitors, ARBs, RNIs, MRAS, IV and SGLT2 inhibitors either not enough data or known harm but some meds can be used cautiously. Beta blockers especially the beta 1 selective ones like metopol are generally preferred. Furismide can be used carefully to manage fluid but you have to avoid dehydration. Dioxin seems safe though doses might need adjusting and hydrollazine combined with nitrates is another option but with any of these you need really close monitoring of the baby. Then for breastfeeding the picture is still evolving for some. Beta blockers like metoprol seem okay. Fioamide and spironolactone also seem to have minimal transfer into milk. Some ACE inhibitors inpro fosynopril quinappil ramiprol are generally thought to be compatible. However, you generally want to avoid arbs aonizabdine and sgt2 inhibitors while breastfeeding.
And the combination of nitrates and hydrolysine,
that combo has a specific place. It's useful for patients who can't tolerate ACE inhibitors, ARBs, or ARNIs, maybe because of kidney problems or high potassium. It's also used as an add-on therapy, particularly in black patients, where studies have shown a specific benefit.
Lastly, 5V iron replacement. This one sometimes surprises people.
It's really important for HFREF patients who are iron deficient, and this is key whether they have anemia or not. Studies show IV iron improves their exercise ability, quality of life, and cuts down hospitalizations. And another key point. Oral iron isn't recommended for this specific reason in heart failure. It just doesn't seem to be absorbed or used effectively in the same way.
Expert, just to wrap up HFREF, what's on the pharmacist's danger zone list? Which drugs should we really avoid or use with extreme caution in these patients?
Knowing what to avoid is just as important. Generally, avoid non-dihydropodine calcium channel blockers dilazasmapl because they can weaken the heart's contraction negative inotropic effects. Most Antiarythmics are also generally not recommended except maybe amodderone for very specific reasons as they don't reduce mortality. Statins are a bit different. If a patient is already on one for coronary artery disease, you generally continue it, but you wouldn't start a statin just for the heart failure itself.
Okay, let's shift gears now to heart failure with preserved ejection fraction or HFPF. You mentioned earlier the treatment landscape here has historically been well pretty challenging.
Yeah, traditionally treating HFTPF was mostly about managing the underlying conditions. hypertension, diabetes, aphib controlling fluid volume and trying to improve quality of life. The big challenge was finding drugs that actually reduced mortality unlike the clear wins we saw in HFREF.
But you hinted that this is where things are really starting to change. What's the big news in HFPF treatment?
This is really exciting actually. The SGLT2 inhibitors specifically in pagaloploin are the only drug class right now that has definitively shown improvement in HFPF in the large trials. They mainly work by reducing heartfield your hospitalizations. That's a huge step forward. Also, MRAs like spironolactone should definitely be considered for symptomatic HFPF patients as long as their potassium and kidney function, EGFR, are okay.
Now, let's tackle a really complex highstakes area. Heart failure during pregnancy and breastfeeding. It sounds like it needs very careful navigation.
Oh, absolutely. It's like walking a tight rope. Pregnancy itself puts a lot of strain on the cardiovascular system, which is risky for someone with existing heart failure. We have to constantly balance the mom heart health needs against the potential risks to the baby because yeah a lot of standard HF meds are territogenic. So during pregnancy itself several drugs are definite no-go. ACC inhibitors, ARBs, RNIs, MRAS, IV and SGLT2 inhibitors either not enough data or known harm but some meds can be used cautiously. Beta blockers especially the beta 1 selective ones like metopol are generally preferred. Furismide can be used carefully to manage fluid but you have to avoid dehydration. Dioxin seems safe though doses might need adjusting and hydrollazine combined with nitrates is another option but with any of these you need really close monitoring of the baby. Then for breastfeeding the picture is still evolving for some. Beta blockers like metoprol seem okay. Fioamide and spironolactone also seem to have minimal transfer into milk. Some ACE inhibitors inpro fosynopril quinappil ramiprol are generally thought to be compatible. However, you generally want to avoid arbs aonizabdine and sgt2 inhibitors while breastfeeding.
just because there isn't much data on their safety.
Expert, this is where theory meets practice for our listeners. Let's boil down some final crucial therapeutic tips. Those practical bite-sized nuggets for daily work and naturally for the PBC exam.
Okay, first off, remember the approach to diuretics is basically the same regardless of HF type. Always aim for the lowest effective dose and constantly reassess their fluid status. Now, if you see hypotension or worsening kidney function when starting or upping the dose of an ACE inhibitor, AR B, RNI or SGLT2 inhibitor. That often signals you need to back off the diuretic dose. It's also really important to realize that sometimes worsening kidney function in HF is actually a sign of congestion and it can often get better once you get rid of the excess fluid with proper diuresis. For HFREF, remember that quadruple therapy goal, but the initiation order is flexible. Tailor it to the patient. The big goal is get all four started and optimize target or best tolerated dose within about 3 to 6 months. And you don't have to max out one before starting the next. You can overlap and titrate together. Specifics: ivabberdine, don't start it unless the beta blocker is already optimized. Max that out first and no ivabberdine if they have aphib. If blood pressure is an issue, maybe try staggering the doses of their anti-hypertensives throughout the day instead of all at once. That cough could be HF getting worse, not just the ACE inhibitor. Always evaluate carefully. Electrolytes. Watch them like a hawk. Especially potassium when you combine drugs like an ACE or Barney with sparolactone. Check creatinine and electrolytes 7 to 14 15 days after starting or changing doses of ACIS, ARBs, ARIS, MRAS, or diuretics. And finally, the crucial sick day management rule. Tell patients to hold their AC inhibitors, ARBs, ARNIs, MRAS, and SGLT2 inhibitors if they get an acute illness that causes dehydration like bad diarrhea or vomiting. This helps prevent acute kidney injury when they're vulnerable.
Wow, that was quite the deep dive into heart failure management. We've covered a lot. The basics, non-drug approaches, the big pharmarmacologic strategies like quadruple therapy, for HFREF, the shifts in HFPEF, even those tricky special situations like pregnancy. Our real aim today for all you Canadian PBC candidates listening was to bring some clarity, accuracy, and those practical insights you need. Hopefully, you feel a bit more confident tackling this really complex but vital topic for your exams and your future practice.
Absolutely. Really understanding these details from the CTC reference, it builds such a strong foundation, not just for the exam, but for taking care of patients dayto-day.
So, As you think back on everything we've talked about today, considering how dynamic heart failure is, here's something to ponder. What do you think is the single most important thing for pharmacists to continuously monitor in their patients beyond just checking if they're taking their meds to ensure the best long-term outcomes? And just to test your recall from our discussion, here's a quick multiple choice question. Which of the following drug classes used for heart failure with reduced ejection fraction, HFREF, should not be initiated or have its dose increased when a patient is acutely decompensated. A loop diuretics, B ACC inhibitors, C beta blockers, D mineralcorticoid receptor antagonists.
Take a second to think about it. We've definitely covered this. The answer is C beta blockers.
Thank you so much for joining us on this deep dive. We really hope this session helps you on your learning journey.
Expert, this is where theory meets practice for our listeners. Let's boil down some final crucial therapeutic tips. Those practical bite-sized nuggets for daily work and naturally for the PBC exam.
Okay, first off, remember the approach to diuretics is basically the same regardless of HF type. Always aim for the lowest effective dose and constantly reassess their fluid status. Now, if you see hypotension or worsening kidney function when starting or upping the dose of an ACE inhibitor, AR B, RNI or SGLT2 inhibitor. That often signals you need to back off the diuretic dose. It's also really important to realize that sometimes worsening kidney function in HF is actually a sign of congestion and it can often get better once you get rid of the excess fluid with proper diuresis. For HFREF, remember that quadruple therapy goal, but the initiation order is flexible. Tailor it to the patient. The big goal is get all four started and optimize target or best tolerated dose within about 3 to 6 months. And you don't have to max out one before starting the next. You can overlap and titrate together. Specifics: ivabberdine, don't start it unless the beta blocker is already optimized. Max that out first and no ivabberdine if they have aphib. If blood pressure is an issue, maybe try staggering the doses of their anti-hypertensives throughout the day instead of all at once. That cough could be HF getting worse, not just the ACE inhibitor. Always evaluate carefully. Electrolytes. Watch them like a hawk. Especially potassium when you combine drugs like an ACE or Barney with sparolactone. Check creatinine and electrolytes 7 to 14 15 days after starting or changing doses of ACIS, ARBs, ARIS, MRAS, or diuretics. And finally, the crucial sick day management rule. Tell patients to hold their AC inhibitors, ARBs, ARNIs, MRAS, and SGLT2 inhibitors if they get an acute illness that causes dehydration like bad diarrhea or vomiting. This helps prevent acute kidney injury when they're vulnerable.
Wow, that was quite the deep dive into heart failure management. We've covered a lot. The basics, non-drug approaches, the big pharmarmacologic strategies like quadruple therapy, for HFREF, the shifts in HFPEF, even those tricky special situations like pregnancy. Our real aim today for all you Canadian PBC candidates listening was to bring some clarity, accuracy, and those practical insights you need. Hopefully, you feel a bit more confident tackling this really complex but vital topic for your exams and your future practice.
Absolutely. Really understanding these details from the CTC reference, it builds such a strong foundation, not just for the exam, but for taking care of patients dayto-day.
So, As you think back on everything we've talked about today, considering how dynamic heart failure is, here's something to ponder. What do you think is the single most important thing for pharmacists to continuously monitor in their patients beyond just checking if they're taking their meds to ensure the best long-term outcomes? And just to test your recall from our discussion, here's a quick multiple choice question. Which of the following drug classes used for heart failure with reduced ejection fraction, HFREF, should not be initiated or have its dose increased when a patient is acutely decompensated. A loop diuretics, B ACC inhibitors, C beta blockers, D mineralcorticoid receptor antagonists.
Take a second to think about it. We've definitely covered this. The answer is C beta blockers.
Thank you so much for joining us on this deep dive. We really hope this session helps you on your learning journey.
تدابیر پس از سکته قلبی
Welcome to the deep dive. If you're gearing up for your PVE C exam, you know that feeling, right? It's just tons of information. Our job here is to cut through all that.
Exactly. We want to distill these big topics into uh really essential digestible insights, give you that critical knowledge so you feel confident, especially for high stakes exams like the PBC.
And today we are diving deep into post-ioardial infarction management. You know, MI is absolutely crucial stuff for any pharmacy. this and definitely for your PPC.
Yeah, we're talking therapeutic choices, medication algorithms, those key tables from the reference, um, essential tips you need to know.
We'll be covering the what, but also the why it matters.
And this deep dive is probably brought to you by the Pharma Board group. Everything we're discussing is based on the postmioardial infuction chapter from the CTC reference. We're aiming for clarity, accuracy, and, you know, practical insights.
So, expect a concise, easy to follow summary. We want you to feel that peace of mind knowing you haven't missed the crucial bits for M success. Okay, let's get started.
Sounds good.
So, let's unpack this first. Post-mocardial infuction. What exactly are we talking about here?
Right. So, this applies to patients who've had either a STEMI, you know, an ST elevation MI or an N STEMI, a non-ST elevation MI. Now, the early the acute management that differs initially.
Okay.
But the key thing is the long-term therapeutic goals, they become quite similar for both groups. We're shifting focus,
right? Moving from the immediate crisis to uh uh sustained recovery. So what are those long-term goals then?
Well, there are three main ones really critical. First, getting patients back to an ideal quality of life. That's huge.
Second, preventing the progression of their disease, their underlying coronary artery disease,
right? Stop it from getting worse.
Exactly. And third, maybe the most critical, preventing a repeat infuction. It's all about keeping them healthy long term.
Makes total sense. Get them back on their feet, keep them healthy. So, what specific complications should pharmacists be watching out for postMI? Good question. We evaluate for several things. Uh LV dysfunction is a big one. Left ventricular dysfunction that can lead to heart failure or arrhythmias.
Okay.
We also look for an LV clot, a blood clot inside the left ventricle that carries a real risk of stroke.
And then there are mechanical complications, things like ventricular septal defects, especially if the MI wasn't reperused quickly or effectively. And of course, ongoing monitoring for potential arhythmias.
Okay, so before we jump into the treatments, the how what are the key investigations the tests that help us figure out risk and guide those treatment choices
right we need to assess risk and guide therapy uh coronary angography is key evidence supports using it early for most STEMI and NTEMI patients it lets us see the blockages
then for lower risk patients
for lower risk and STEMI patients sometimes stress testing is used first but if that shows high risk then angography is still needed
and what about checking the actual damage the heart function itself
oh absolutely vital. We need to assess the infark size or left ventricular function, usually shortened to LV function. A significantly diminished ejection fraction or EF, that means the heart isn't pumping well, puts patients at higher risk
higher risk for
for things like LV thrombus, heart failure, and arrhythmias. Yeah.
An echo cardiogram is really the go-to for assessing LV function and looking for clots.
And do you repeat that assessment?
Yes, definitely. We typically repeat the LV function evaluation at uh 1 month if they weren't revascularized or 3 months if they were that's if the LVEF was initially low say less than 30 35% it helps decide if they might need an implantable defibrillator an ICD
Welcome to the deep dive. If you're gearing up for your PVE C exam, you know that feeling, right? It's just tons of information. Our job here is to cut through all that.
Exactly. We want to distill these big topics into uh really essential digestible insights, give you that critical knowledge so you feel confident, especially for high stakes exams like the PBC.
And today we are diving deep into post-ioardial infarction management. You know, MI is absolutely crucial stuff for any pharmacy. this and definitely for your PPC.
Yeah, we're talking therapeutic choices, medication algorithms, those key tables from the reference, um, essential tips you need to know.
We'll be covering the what, but also the why it matters.
And this deep dive is probably brought to you by the Pharma Board group. Everything we're discussing is based on the postmioardial infuction chapter from the CTC reference. We're aiming for clarity, accuracy, and, you know, practical insights.
So, expect a concise, easy to follow summary. We want you to feel that peace of mind knowing you haven't missed the crucial bits for M success. Okay, let's get started.
Sounds good.
So, let's unpack this first. Post-mocardial infuction. What exactly are we talking about here?
Right. So, this applies to patients who've had either a STEMI, you know, an ST elevation MI or an N STEMI, a non-ST elevation MI. Now, the early the acute management that differs initially.
Okay.
But the key thing is the long-term therapeutic goals, they become quite similar for both groups. We're shifting focus,
right? Moving from the immediate crisis to uh uh sustained recovery. So what are those long-term goals then?
Well, there are three main ones really critical. First, getting patients back to an ideal quality of life. That's huge.
Second, preventing the progression of their disease, their underlying coronary artery disease,
right? Stop it from getting worse.
Exactly. And third, maybe the most critical, preventing a repeat infuction. It's all about keeping them healthy long term.
Makes total sense. Get them back on their feet, keep them healthy. So, what specific complications should pharmacists be watching out for postMI? Good question. We evaluate for several things. Uh LV dysfunction is a big one. Left ventricular dysfunction that can lead to heart failure or arrhythmias.
Okay.
We also look for an LV clot, a blood clot inside the left ventricle that carries a real risk of stroke.
And then there are mechanical complications, things like ventricular septal defects, especially if the MI wasn't reperused quickly or effectively. And of course, ongoing monitoring for potential arhythmias.
Okay, so before we jump into the treatments, the how what are the key investigations the tests that help us figure out risk and guide those treatment choices
right we need to assess risk and guide therapy uh coronary angography is key evidence supports using it early for most STEMI and NTEMI patients it lets us see the blockages
then for lower risk patients
for lower risk and STEMI patients sometimes stress testing is used first but if that shows high risk then angography is still needed
and what about checking the actual damage the heart function itself
oh absolutely vital. We need to assess the infark size or left ventricular function, usually shortened to LV function. A significantly diminished ejection fraction or EF, that means the heart isn't pumping well, puts patients at higher risk
higher risk for
for things like LV thrombus, heart failure, and arrhythmias. Yeah.
An echo cardiogram is really the go-to for assessing LV function and looking for clots.
And do you repeat that assessment?
Yes, definitely. We typically repeat the LV function evaluation at uh 1 month if they weren't revascularized or 3 months if they were that's if the LVEF was initially low say less than 30 35% it helps decide if they might need an implantable defibrillator an ICD
okay and of course alongside all this we're looking at those modifiable risk factors smoking blood pressure BMI cholesterol glucose all that standard stuff
absolutely tackling those is fundamental
so moving on to therapeutic choices before we get into the medications what about non-drug therapies these are often just as important aren't they
they absolutely absolutely are foundational really
no
beyond the coronary angography we mentioned key non-farmacologic strategies include weight management the target BMI is 18.5 to 25
and waist circumference
less than 100 cm for men less than 90 cm for women often aiming for a 5 to 10% weight decrease initially
okay
nutritional counseling is vital and regular exercise like 30 45 minutes of moderate aerobic activity maybe 3 four times a week the goal is burning around 1,000 kiloal per week through activity.
What about the mental health side? MI can be pretty traumatic.
Very true. Individual or group counseling for psychosocial issues like anxiety or depression is important and for some select patients, the ones with significant persistent LV dysfunction, an implantable cardioverter defibrillator, ICD, might be needed down the line.
Right now, here's where it gets really interesting for secondary prevention and definitely something for PBC candidates to note. The source highlights this concept called the power of four.
Yes, this is a critical Takeaway. After an MI, patients are at substantial risk for Macy major adverse cardiovascular events. What's really powerful is that using four key drug classes independently reduces MCE by about 25% each.
25% each
each. And if you use all four drug classes together, the cumulative relative risk reduction is approximately 75%. You can see this laid out clearly in table one in the CTC reference.
Wow, 75%. That is a massive potential benefit. So it's Not just additive, it's synergistic.
Exactly. It highlights the importance of comprehensive medical therapy.
You lay out those power four drug classes for us.
Sure. First, ASA aspirin gives you about a 25% relative risk reduction.
Okay.
Second, beta blockers. Another 25% RR,
right?
Third, lipid lowering agents, primarily statins. These provide around a 30% RR, especially when they lower LDLC by about 1.5 millol.
Got it. And the fourth
fourth is an ACE inhibitor contributing another 25% RR.
So, So add those up roughly 75%. And the source also mentions smoking sessation can cut recurrent MI risk of by half after 2 years.
That's right.
So theoretically, you combine all of that, the four drug classes plus quitting smoking, and you could be looking at something like an 80% relative risk reduction. That's well that's an aha moment right there.
It truly underscores the impact we can have with evidence-based secondary prevention.
Absolutely. Okay, let's dive deeper into these pharmacologic agents. Starting with the antiplatlets. MI involves plaque rupture active ated platelets. So platelet inhibition is key, right?
No. Especially after procedures like PCI. That's why dual antiplatlet therapy or DAPT using ASA plus a P2Y12 inhibitor is so crucial initially.
Let's break them down. ASA what are the key points for pharmacists?
Okay, ASA it's indefinite therapy for basically all postinfar patients
and importantly low dose like 7500 milligrams is just as effective as higher doses but usually better tolerated less bleeding risk.
Makes sense. What about clapidogil?
Clapidogil is very common especially after PCI. Uh sometimes a higher dose 150 milligrams daily is used for the first six days post PCI and stem and STEMI then down to the standard 75 milligrams daily. It's also the main alternative if someone has an ASA allergy.
Okay. Then there's prugil sounds more potent.
It is more potent faster onset. Often considered firstline post in STEMI or STEMI but and this is a big butt for exams you absolutely avoid it in patient with a prior stroke or TIA.
Crucial point. Any other cautions?
Yeah, caution in patients over 75 or who weigh less than 60 kg.
absolutely tackling those is fundamental
so moving on to therapeutic choices before we get into the medications what about non-drug therapies these are often just as important aren't they
they absolutely absolutely are foundational really
no
beyond the coronary angography we mentioned key non-farmacologic strategies include weight management the target BMI is 18.5 to 25
and waist circumference
less than 100 cm for men less than 90 cm for women often aiming for a 5 to 10% weight decrease initially
okay
nutritional counseling is vital and regular exercise like 30 45 minutes of moderate aerobic activity maybe 3 four times a week the goal is burning around 1,000 kiloal per week through activity.
What about the mental health side? MI can be pretty traumatic.
Very true. Individual or group counseling for psychosocial issues like anxiety or depression is important and for some select patients, the ones with significant persistent LV dysfunction, an implantable cardioverter defibrillator, ICD, might be needed down the line.
Right now, here's where it gets really interesting for secondary prevention and definitely something for PBC candidates to note. The source highlights this concept called the power of four.
Yes, this is a critical Takeaway. After an MI, patients are at substantial risk for Macy major adverse cardiovascular events. What's really powerful is that using four key drug classes independently reduces MCE by about 25% each.
25% each
each. And if you use all four drug classes together, the cumulative relative risk reduction is approximately 75%. You can see this laid out clearly in table one in the CTC reference.
Wow, 75%. That is a massive potential benefit. So it's Not just additive, it's synergistic.
Exactly. It highlights the importance of comprehensive medical therapy.
You lay out those power four drug classes for us.
Sure. First, ASA aspirin gives you about a 25% relative risk reduction.
Okay.
Second, beta blockers. Another 25% RR,
right?
Third, lipid lowering agents, primarily statins. These provide around a 30% RR, especially when they lower LDLC by about 1.5 millol.
Got it. And the fourth
fourth is an ACE inhibitor contributing another 25% RR.
So, So add those up roughly 75%. And the source also mentions smoking sessation can cut recurrent MI risk of by half after 2 years.
That's right.
So theoretically, you combine all of that, the four drug classes plus quitting smoking, and you could be looking at something like an 80% relative risk reduction. That's well that's an aha moment right there.
It truly underscores the impact we can have with evidence-based secondary prevention.
Absolutely. Okay, let's dive deeper into these pharmacologic agents. Starting with the antiplatlets. MI involves plaque rupture active ated platelets. So platelet inhibition is key, right?
No. Especially after procedures like PCI. That's why dual antiplatlet therapy or DAPT using ASA plus a P2Y12 inhibitor is so crucial initially.
Let's break them down. ASA what are the key points for pharmacists?
Okay, ASA it's indefinite therapy for basically all postinfar patients
and importantly low dose like 7500 milligrams is just as effective as higher doses but usually better tolerated less bleeding risk.
Makes sense. What about clapidogil?
Clapidogil is very common especially after PCI. Uh sometimes a higher dose 150 milligrams daily is used for the first six days post PCI and stem and STEMI then down to the standard 75 milligrams daily. It's also the main alternative if someone has an ASA allergy.
Okay. Then there's prugil sounds more potent.
It is more potent faster onset. Often considered firstline post in STEMI or STEMI but and this is a big butt for exams you absolutely avoid it in patient with a prior stroke or TIA.
Crucial point. Any other cautions?
Yeah, caution in patients over 75 or who weigh less than 60 kg.
❤1
Sometimes a reduced dose is considered there if available.
Got it. And tuggler.
Turguler is also considered first line. Studies show it's more effective than clapadril in ACS. But you need to be aware of potential adverse effects. Bleeding obviously, but also transient dispna, shortness of breath, which happens in about 14% of patients.
Okay. Now, the duration of DPT How long do patients typically stay on both?
That's a really important clinical question. The standard recommendation is at least 1 year after MI, especially if the bleeding risk is low.
At least 1 year. Can it be longer?
Yes. In some patients, there might be a benefit to extending it, maybe up to 3 years. There are tools like the DPT risk calculator that can help weigh the benefit against the bleeding risk, but it's always balance, always individualized.
And what about that combination you mentioned earlier, Riveroxin with aspirin?
Right. That's an option further down the line. Usually, at the one-year mark for stable coronary disease. It's river oxen 2.5 milligrams twice daily with lowd dose aspirin. It's particularly considered in patients who also have peripheral vascular disease or maybe a high stroke risk. Adds another layer of anti-thrombotic protection.
Okay, moving on. Beta blockers. You mentioned they're one of the power of four. What's their specific role postmi?
Beta blockers are fascinating. They reduce reinfarction, yes, but they also play a key role in preventing dangerous ventricular arithm. as especially in that early postMI phase.
So who should get them?
They should really be considered in all patients post STEMI or N STEMI unless there's a clear contraindication. The goal is usually to titrate the dose to get the resting heart rate below 70 beats per minute.
Any cautions with beta blockers?
Definitely you need to be cautious with IV beta blockers right at the start in the acute phase because of potential hemodynamic instability and you'd avoid them altogether in patients with significant hypotension, bradic cardia or active heart failure
and long-term use.
Patients with reduced LV function, that low ejection fraction we talked about, they get significant long-term benefit. For them, beta blockers should generally be continued indefinitely.
Okay, next group. RAA is inhibition. That's AC inhibitors, ARBs, and MRAs. This raises a key question. Who really gets the most benefit from these after an MI?
Good question. ACE inhibitors should be considered for all postMI patients, but they're especially beneficial for those with V dysfunction meaning LVF less than 40% or those who also have hypertension or diabetes.
Why are they so beneficial?
They help prevent negative LV remodeling changes in the heart's shape and function after damage and they've been shown to reduce cardiovascular death and recurrent MI.
What should pharmacists watch for?
The main things are that dry cough which is quite common and potential issues like worsening renal function or hypercalemia hypotassium. So monitoring is key and it's important to titrate them up to the evidence-based dosages like those listed in table two of the reference,
right? Table two for target doses. And if someone can't tolerate an ACE inhibitor because of the cough,
then an ARB, an angotensin receptor blocker, is the standard alternative. They work similarly, but don't typically cause cough.
Can you use both together? AC inhibitor and ARB?
No, absolutely not. That combination therapy doesn't add benefit and actually increases the risk of adverse events like hypercalemia and renal dysfunction. So, it's one or the other.
Okay. And the MRA's mineral corticoid receptor antagonists,
right? Agents like epinon or spironolactone. These should be considered specifically in patients who already have significant LV dysfunction. So, EF less than or equal to 40% often alongside an AC or ARB and a beta blocker. Eperon in particular has shown reduced mortality and hospitalizations in this group.
Main caution with MRAAS.
Got it. And tuggler.
Turguler is also considered first line. Studies show it's more effective than clapadril in ACS. But you need to be aware of potential adverse effects. Bleeding obviously, but also transient dispna, shortness of breath, which happens in about 14% of patients.
Okay. Now, the duration of DPT How long do patients typically stay on both?
That's a really important clinical question. The standard recommendation is at least 1 year after MI, especially if the bleeding risk is low.
At least 1 year. Can it be longer?
Yes. In some patients, there might be a benefit to extending it, maybe up to 3 years. There are tools like the DPT risk calculator that can help weigh the benefit against the bleeding risk, but it's always balance, always individualized.
And what about that combination you mentioned earlier, Riveroxin with aspirin?
Right. That's an option further down the line. Usually, at the one-year mark for stable coronary disease. It's river oxen 2.5 milligrams twice daily with lowd dose aspirin. It's particularly considered in patients who also have peripheral vascular disease or maybe a high stroke risk. Adds another layer of anti-thrombotic protection.
Okay, moving on. Beta blockers. You mentioned they're one of the power of four. What's their specific role postmi?
Beta blockers are fascinating. They reduce reinfarction, yes, but they also play a key role in preventing dangerous ventricular arithm. as especially in that early postMI phase.
So who should get them?
They should really be considered in all patients post STEMI or N STEMI unless there's a clear contraindication. The goal is usually to titrate the dose to get the resting heart rate below 70 beats per minute.
Any cautions with beta blockers?
Definitely you need to be cautious with IV beta blockers right at the start in the acute phase because of potential hemodynamic instability and you'd avoid them altogether in patients with significant hypotension, bradic cardia or active heart failure
and long-term use.
Patients with reduced LV function, that low ejection fraction we talked about, they get significant long-term benefit. For them, beta blockers should generally be continued indefinitely.
Okay, next group. RAA is inhibition. That's AC inhibitors, ARBs, and MRAs. This raises a key question. Who really gets the most benefit from these after an MI?
Good question. ACE inhibitors should be considered for all postMI patients, but they're especially beneficial for those with V dysfunction meaning LVF less than 40% or those who also have hypertension or diabetes.
Why are they so beneficial?
They help prevent negative LV remodeling changes in the heart's shape and function after damage and they've been shown to reduce cardiovascular death and recurrent MI.
What should pharmacists watch for?
The main things are that dry cough which is quite common and potential issues like worsening renal function or hypercalemia hypotassium. So monitoring is key and it's important to titrate them up to the evidence-based dosages like those listed in table two of the reference,
right? Table two for target doses. And if someone can't tolerate an ACE inhibitor because of the cough,
then an ARB, an angotensin receptor blocker, is the standard alternative. They work similarly, but don't typically cause cough.
Can you use both together? AC inhibitor and ARB?
No, absolutely not. That combination therapy doesn't add benefit and actually increases the risk of adverse events like hypercalemia and renal dysfunction. So, it's one or the other.
Okay. And the MRA's mineral corticoid receptor antagonists,
right? Agents like epinon or spironolactone. These should be considered specifically in patients who already have significant LV dysfunction. So, EF less than or equal to 40% often alongside an AC or ARB and a beta blocker. Eperon in particular has shown reduced mortality and hospitalizations in this group.
Main caution with MRAAS.
Again, hypercalemia, you really need to monitor electrolytes closely when these are added.
Makes sense. Now, statins, you said they're part of the power for contributing about 30% risk reduction seems like a cornerstone.
Absolutely a definite cornerstone. Statins should be started early postMI and importantly we generally aim for intensive treatment with higher dose statins
like which ones?
Like avoatin 80 milligrams daily or rosatin 40 milligs daily. The benefit goes beyond just lowering LDL cholesterol. They also help stabilize plaques making them less likely to rupture.
And the goal for LDL
for postMI patients the target is an LDLC of less than 1 and 8 millol therapy is indefinite. It's a long-term commitment.
What if someone is statin intolerant?
If they genuinely can't tolerate statins despite trying different ones, then other agents like aetime or even PCSK9 inhibitors might be considered to reach that LDL target.
Okay, that covers the core medications for most patients. But things can get trickier. What about patients who need oral anti-coagulants, maybe for AIB or an LV thrombus? How does that interact with DIPT?
Yeah, this is where it definitely gets complex, especially managing the bleeding risk. Oral anti-coagulants are recommended postMI if the patient also has atrial fibrillation AIB or if they have a demonstrable LV thrombus.
Let's take LV thrombus first. Which anti-coagulant
for LV thrombus? Warin is still generally the anti-coagulant of choice. There's just not enough solid evidence for using the DOAC's the direct acting oral anti-coagulants in this specific situation yet.
How long do they stay on warin for the thrombus?
Typically treatment is for about 3 months. Then you'd repeat the echo cardiogram if the thrombus is gone you can consider stopping the warin assuming there's no other indication like aphib
okay and for patients with atrial fibrillation postmi
for aphib the docs like river ox bandan daba pixaban adoxaban are generally preferred especially when they need to be combined with a p2y12 inhibitor
because of the bleeding risk with triple therapy
exactly triple therapy meaning ASA a P2Y12 inhibitor and warerin carries a significantly increased bleeding risk several big trials like pioneer AFPCI dual PCI. Augustus and Trust looked at this
and what did they find?
They explored safer strategies often involving stopping the ASA early, sometimes as early as day one after PCI or maybe up to 6 months and just continuing with the DOAC plus a P2Y12 inhibitor usually cla
so if triple therapy is needed even for a short time which P2Y12 inhibitor is preferred with Warin.
If warrin has to be used with dual antiplatelets cloped is often the preferred P2i12 inhibitor. studies suggest it might have a lower bleeding risk compared to prashagril or dicagriller in that specific triple combination but these are complex decisions always need individualization and cardiologist input
definitely sounds complex okay let's shift gears slightly to special populations what's unique about managing MI during pregnancy or breastfeeding
right MI in pregnancy is rare thankfully but when it happens the most common cause isn't typical plaque rupture it's often spontaneous coronary artery dissection or scad
how is scad managed differently.
SCAD is usually managed more conservatively, often with medications rather than immediate stenting unless there's ongoing eskeeia. DAPT, beta blockers, and ACE inhibitors if there's LV dysfunction might be considered. But a key point, statins are generally not indicated for SCAD unless the patient also has underlying atheroscllerotic CAD.
Okay. And during breastfeeding, what are the concerns?
There are definite concerns for the infant. ASA and lowd dose beta blockers can sometimes be used cautiously. However, if the mother needs P2Y12 inhibitors, ACCE inhibitors or statins, breastfeeding is generally not recommended. The risks are usually considered too high.
Got it. So, bringing this all together for our PBC candidates listening.
Makes sense. Now, statins, you said they're part of the power for contributing about 30% risk reduction seems like a cornerstone.
Absolutely a definite cornerstone. Statins should be started early postMI and importantly we generally aim for intensive treatment with higher dose statins
like which ones?
Like avoatin 80 milligrams daily or rosatin 40 milligs daily. The benefit goes beyond just lowering LDL cholesterol. They also help stabilize plaques making them less likely to rupture.
And the goal for LDL
for postMI patients the target is an LDLC of less than 1 and 8 millol therapy is indefinite. It's a long-term commitment.
What if someone is statin intolerant?
If they genuinely can't tolerate statins despite trying different ones, then other agents like aetime or even PCSK9 inhibitors might be considered to reach that LDL target.
Okay, that covers the core medications for most patients. But things can get trickier. What about patients who need oral anti-coagulants, maybe for AIB or an LV thrombus? How does that interact with DIPT?
Yeah, this is where it definitely gets complex, especially managing the bleeding risk. Oral anti-coagulants are recommended postMI if the patient also has atrial fibrillation AIB or if they have a demonstrable LV thrombus.
Let's take LV thrombus first. Which anti-coagulant
for LV thrombus? Warin is still generally the anti-coagulant of choice. There's just not enough solid evidence for using the DOAC's the direct acting oral anti-coagulants in this specific situation yet.
How long do they stay on warin for the thrombus?
Typically treatment is for about 3 months. Then you'd repeat the echo cardiogram if the thrombus is gone you can consider stopping the warin assuming there's no other indication like aphib
okay and for patients with atrial fibrillation postmi
for aphib the docs like river ox bandan daba pixaban adoxaban are generally preferred especially when they need to be combined with a p2y12 inhibitor
because of the bleeding risk with triple therapy
exactly triple therapy meaning ASA a P2Y12 inhibitor and warerin carries a significantly increased bleeding risk several big trials like pioneer AFPCI dual PCI. Augustus and Trust looked at this
and what did they find?
They explored safer strategies often involving stopping the ASA early, sometimes as early as day one after PCI or maybe up to 6 months and just continuing with the DOAC plus a P2Y12 inhibitor usually cla
so if triple therapy is needed even for a short time which P2Y12 inhibitor is preferred with Warin.
If warrin has to be used with dual antiplatelets cloped is often the preferred P2i12 inhibitor. studies suggest it might have a lower bleeding risk compared to prashagril or dicagriller in that specific triple combination but these are complex decisions always need individualization and cardiologist input
definitely sounds complex okay let's shift gears slightly to special populations what's unique about managing MI during pregnancy or breastfeeding
right MI in pregnancy is rare thankfully but when it happens the most common cause isn't typical plaque rupture it's often spontaneous coronary artery dissection or scad
how is scad managed differently.
SCAD is usually managed more conservatively, often with medications rather than immediate stenting unless there's ongoing eskeeia. DAPT, beta blockers, and ACE inhibitors if there's LV dysfunction might be considered. But a key point, statins are generally not indicated for SCAD unless the patient also has underlying atheroscllerotic CAD.
Okay. And during breastfeeding, what are the concerns?
There are definite concerns for the infant. ASA and lowd dose beta blockers can sometimes be used cautiously. However, if the mother needs P2Y12 inhibitors, ACCE inhibitors or statins, breastfeeding is generally not recommended. The risks are usually considered too high.
Got it. So, bringing this all together for our PBC candidates listening.
What are the absolute essential therapeutic tips, the practical insights they need to nail down for exam success and good practice?
Okay, this is really about maximizing adherence and outcomes. Think of it maybe three parts. First, maximize drug effectiveness. That means ensuring close adherence to these evidence-based therapies. Starting them early in hospital helps. Also, ongoing dosage titration. Keep pushing those beta blockers and ACE inhibitors towards the target doses found in table 2 as tolerated. And for statins, use the highest tolerated dose. Yeah.
Don't settle for less if more is possible.
Okay. Effectiveness first. What's second?
Second, empower the patient through lifestyle. Offer smoking sessation support. Bropion or verenocline are considered safe early postmi. And strongly encourage cardiac rehabilitation. makes a huge difference.
And third,
third, be vigilant about coorbidities and pitfalls. Manage blood pressure to target. Treat diabetes aiming for an HBA1C generally under 7%.
Any specific drug cautions we should highlight again?
Yes, definitely avoid thosol and those diabetes drugs like pyoglazone because of the heart failure risk. Make sure patients have sublingual nitrates and know exactly how and when to use them for chest discomfort.
Good point on the nitrates. Anything else?
Encourage annual flu vaccination. Be aware of depression. It's common postMI and SSRIs might help. And definitely know what not to use.
Like what?
Routine antioxidant vitamins or hormone therapy for secondary prevention. Not recommended, potentially harmful. And the big one, avoid anesides if possible.
Why avoid NSAIDs?
They can increase athermotic risk or interfere with ASA's effect. Especially avoid celoxip and ibuprofen if you can. If an NSA is absolutely necessary, naproxen is generally considered to have the least cardiovascular risk among them.
Okay, that's Great summary of tips. And finally, those algorithms and tables in the reference figures 1 2 3 and table two. How should listeners best use those for studying?
They are incredibly valuable study tools. Figures 1, 2, and three really map out the decision-m especially for those complex antiplate lantic coagulant choices like an AIB postci. They show how different factors influence the drug choice and duration.
What should they pay close attention to in the figures?
Definitely read the footnotes. They contain critical details, nuances, etcept. And two is your go-to for specific drug details, dosages, key adverse effects, major interactions, perfect for exam.
Fantastic. So listeners, you've just had a really comprehensive deep dive into postMI management. We've covered the goals, the core therapies, those tricky anti-coagulant situations, special populations, and essential tips, all geared towards your PBC success.
Yeah, our aim was clarity, accuracy, and hopefully some peace of mind. Summarizing this, critical info so you feel confident you've got the essentials covered. And remember, it's not just knowing what to do, but really understanding why it matters. That's key.
So, what stands out most to you from our chat today? Maybe think about that power of four and how those therapies work together for that impressive cumulative risk reduction.
Or perhaps consider that constant challenge balancing the need to prevent clots, prevent eskeemia against the risk of bleeding, especially in those complex patients needing multiple agents. It really makes you think, how would you counsel a patient? Maybe someone with a history of MI who now has new AIB. How do you explain that complex regimen, the risks, benefits, that careful balance?
Great point. Food for thought. Okay, before we wrap up, let's test your knowledge with a quick multiple choice question based on our deep dive.
All right.
A patient experiences an acute STEMI and underos primary PCI. They are deemed low bleeding risk. According to current guidelines, what is the minimum recommended duration of dual antiplatlet therapy, DAPT, postMI? Is it A 3 months, B 6 months, C 1 year, D 3 years.
Okay, this is really about maximizing adherence and outcomes. Think of it maybe three parts. First, maximize drug effectiveness. That means ensuring close adherence to these evidence-based therapies. Starting them early in hospital helps. Also, ongoing dosage titration. Keep pushing those beta blockers and ACE inhibitors towards the target doses found in table 2 as tolerated. And for statins, use the highest tolerated dose. Yeah.
Don't settle for less if more is possible.
Okay. Effectiveness first. What's second?
Second, empower the patient through lifestyle. Offer smoking sessation support. Bropion or verenocline are considered safe early postmi. And strongly encourage cardiac rehabilitation. makes a huge difference.
And third,
third, be vigilant about coorbidities and pitfalls. Manage blood pressure to target. Treat diabetes aiming for an HBA1C generally under 7%.
Any specific drug cautions we should highlight again?
Yes, definitely avoid thosol and those diabetes drugs like pyoglazone because of the heart failure risk. Make sure patients have sublingual nitrates and know exactly how and when to use them for chest discomfort.
Good point on the nitrates. Anything else?
Encourage annual flu vaccination. Be aware of depression. It's common postMI and SSRIs might help. And definitely know what not to use.
Like what?
Routine antioxidant vitamins or hormone therapy for secondary prevention. Not recommended, potentially harmful. And the big one, avoid anesides if possible.
Why avoid NSAIDs?
They can increase athermotic risk or interfere with ASA's effect. Especially avoid celoxip and ibuprofen if you can. If an NSA is absolutely necessary, naproxen is generally considered to have the least cardiovascular risk among them.
Okay, that's Great summary of tips. And finally, those algorithms and tables in the reference figures 1 2 3 and table two. How should listeners best use those for studying?
They are incredibly valuable study tools. Figures 1, 2, and three really map out the decision-m especially for those complex antiplate lantic coagulant choices like an AIB postci. They show how different factors influence the drug choice and duration.
What should they pay close attention to in the figures?
Definitely read the footnotes. They contain critical details, nuances, etcept. And two is your go-to for specific drug details, dosages, key adverse effects, major interactions, perfect for exam.
Fantastic. So listeners, you've just had a really comprehensive deep dive into postMI management. We've covered the goals, the core therapies, those tricky anti-coagulant situations, special populations, and essential tips, all geared towards your PBC success.
Yeah, our aim was clarity, accuracy, and hopefully some peace of mind. Summarizing this, critical info so you feel confident you've got the essentials covered. And remember, it's not just knowing what to do, but really understanding why it matters. That's key.
So, what stands out most to you from our chat today? Maybe think about that power of four and how those therapies work together for that impressive cumulative risk reduction.
Or perhaps consider that constant challenge balancing the need to prevent clots, prevent eskeemia against the risk of bleeding, especially in those complex patients needing multiple agents. It really makes you think, how would you counsel a patient? Maybe someone with a history of MI who now has new AIB. How do you explain that complex regimen, the risks, benefits, that careful balance?
Great point. Food for thought. Okay, before we wrap up, let's test your knowledge with a quick multiple choice question based on our deep dive.
All right.
A patient experiences an acute STEMI and underos primary PCI. They are deemed low bleeding risk. According to current guidelines, what is the minimum recommended duration of dual antiplatlet therapy, DAPT, postMI? Is it A 3 months, B 6 months, C 1 year, D 3 years.
Okay, take a moment to think. The answer is C 1 year. That's the minimum recommended duration for low bleeding risk patients postMMI after PCI. Longer duration might be considered, but one year is the baseline minimum.
Perfect. We really hope this deep dive has helped clarify postMI management and boosted your confidence for the PBC exams. Remember, this deep dive was brought to you by the Pharma Board Group and it's bas on the essential CTC reference.
Thank you so much for joining us on the deep dive. Keep learning, keep asking those critical questions, and we'll catch you on the next one.
Perfect. We really hope this deep dive has helped clarify postMI management and boosted your confidence for the PBC exams. Remember, this deep dive was brought to you by the Pharma Board Group and it's bas on the essential CTC reference.
Thank you so much for joining us on the deep dive. Keep learning, keep asking those critical questions, and we'll catch you on the next one.
اریتمی فوق بطنی
Welcome to the deep dive. You know, navigating all the medical information out there, especially when you're prepping for big exams like the PBC. Well, it can feel overwhelming, right? Like drinking from a fire hose. Our goal here is really to be your guide, cut through that noise, and get you the core insights you absolutely have to know so you don't miss those crucial details. Basically, we want you to feel confident, clear, and ready. So, today we're taking a really close look, a deep dive into super ventricular attack. cardia SVT. This is a huge topic for you as a Canadian pharmacist candidate. It comes up a lot on exams. You'll definitely see it in practice. We're going to focus on um giving you concise, easy to follow, accurate insights. Think therapeutic choices, medication algorithms, those key tables, and yeah, those vital tips for exam success and for real world practice. Just so you know, this deep dive is brought to you by Pharma Board Group and it's based on the therapeutic choices or CTC reference.
Absolutely. And uh maybe the best place to start is just Defining SVT what is it
fundamentally it's well it's any fast heart rhythm attack that starts above the ventricles usually you'll see a narrow QRS width on the ECG so 120 milliseconds or less
but here's the first absolutely critical step if you see a tacic cardia with a broad QRS complex
your immediate thought your priority has to be ruling out ventricular tacic cardia
oh okay because that's much more dangerous
exactly much more serious you need to exclude that possibility before you start digging into SVT causes.
Got it. So, fast rhythm starts above the ventricles, usually narrow QRS. Okay, unpack this a bit. What are the different types of SVT under this, you know, umbrella and why does knowing the type matter so much for our listeners?
That's a really important question because the type tells us a lot about the risks and uh how we should treat it. So, if we look at the common forms atrial fibrillation, AS and atrial flutter, these two are really significant. Why? Well, it boils down to thrombboic risk.
Well, stroke risk precisely. the danger of blood clots forming and potentially causing a stroke. That risk really drives a lot of the management decisions for AF and flutter. Then you have other types like atrio vventricular nodal re-entry tacocardia that's AVNRT and atrioventricular re-entry tacicardia or AVRT and also focal atrial teacardia at these are generally thought of as more benign uh less likely to cause really serious complications
generally benign
but there's always a butt isn't there with AVRT there is a rare, but um serious risk of sudden death. That can happen if it degenerates into what's called a pre-exited SVT. That's usually linked to accessory pathways.
Okay. And speaking of AF and flutter, I know the way we classify them has changed. The term chronic AF isn't really used anymore, right? Can you walk us through the current terms?
Yeah, that's right. We've moved towards more precise definitions. So, peroxismal AF or flutter, that means the episodes come and go. They stop on their own usually within seven days.
Self-limiting.
Exactly. Then there's persistent That's when the arhythmia is continuous. It lasts more than 7 days but less than say 12 months. After that we have longstanding persistent. This means it's been continuous for over a year but crucially restoring a normal sinus rhythm is still seen as you know a possible goal. And finally permanent AF or flutter. This isn't just about duration. It's a clinical decision. It's when the patient and the clinician together decide to stop trying to get back to or maintain sinus rhythm.
So it's accepting that rate control is the strategy
pretty much. Yes. It acknowledges that for that particular patient, rhythm control isn't feasible or maybe even desirable anymore. Now, while the overall management approach for AF and flutter is quite similar, especially that stroke risk assessment, there are a couple of important differences.
Welcome to the deep dive. You know, navigating all the medical information out there, especially when you're prepping for big exams like the PBC. Well, it can feel overwhelming, right? Like drinking from a fire hose. Our goal here is really to be your guide, cut through that noise, and get you the core insights you absolutely have to know so you don't miss those crucial details. Basically, we want you to feel confident, clear, and ready. So, today we're taking a really close look, a deep dive into super ventricular attack. cardia SVT. This is a huge topic for you as a Canadian pharmacist candidate. It comes up a lot on exams. You'll definitely see it in practice. We're going to focus on um giving you concise, easy to follow, accurate insights. Think therapeutic choices, medication algorithms, those key tables, and yeah, those vital tips for exam success and for real world practice. Just so you know, this deep dive is brought to you by Pharma Board Group and it's based on the therapeutic choices or CTC reference.
Absolutely. And uh maybe the best place to start is just Defining SVT what is it
fundamentally it's well it's any fast heart rhythm attack that starts above the ventricles usually you'll see a narrow QRS width on the ECG so 120 milliseconds or less
but here's the first absolutely critical step if you see a tacic cardia with a broad QRS complex
your immediate thought your priority has to be ruling out ventricular tacic cardia
oh okay because that's much more dangerous
exactly much more serious you need to exclude that possibility before you start digging into SVT causes.
Got it. So, fast rhythm starts above the ventricles, usually narrow QRS. Okay, unpack this a bit. What are the different types of SVT under this, you know, umbrella and why does knowing the type matter so much for our listeners?
That's a really important question because the type tells us a lot about the risks and uh how we should treat it. So, if we look at the common forms atrial fibrillation, AS and atrial flutter, these two are really significant. Why? Well, it boils down to thrombboic risk.
Well, stroke risk precisely. the danger of blood clots forming and potentially causing a stroke. That risk really drives a lot of the management decisions for AF and flutter. Then you have other types like atrio vventricular nodal re-entry tacocardia that's AVNRT and atrioventricular re-entry tacicardia or AVRT and also focal atrial teacardia at these are generally thought of as more benign uh less likely to cause really serious complications
generally benign
but there's always a butt isn't there with AVRT there is a rare, but um serious risk of sudden death. That can happen if it degenerates into what's called a pre-exited SVT. That's usually linked to accessory pathways.
Okay. And speaking of AF and flutter, I know the way we classify them has changed. The term chronic AF isn't really used anymore, right? Can you walk us through the current terms?
Yeah, that's right. We've moved towards more precise definitions. So, peroxismal AF or flutter, that means the episodes come and go. They stop on their own usually within seven days.
Self-limiting.
Exactly. Then there's persistent That's when the arhythmia is continuous. It lasts more than 7 days but less than say 12 months. After that we have longstanding persistent. This means it's been continuous for over a year but crucially restoring a normal sinus rhythm is still seen as you know a possible goal. And finally permanent AF or flutter. This isn't just about duration. It's a clinical decision. It's when the patient and the clinician together decide to stop trying to get back to or maintain sinus rhythm.
So it's accepting that rate control is the strategy
pretty much. Yes. It acknowledges that for that particular patient, rhythm control isn't feasible or maybe even desirable anymore. Now, while the overall management approach for AF and flutter is quite similar, especially that stroke risk assessment, there are a couple of important differences.
First, getting the heart rate under control, it can often be well a bit trickier in atrial flutter compared to AF.
Harder to slow down
often. Yes. And second, and this impacts treatment, the threshold for considering catheter ablation is generally lower for atrial flutter. It tends to respond really well to ablation, often providing a long-term fix.
Makes sense.
And just quickly on those other usually benign SVTs, the mechanisms, AVRT is caused by an extra electrical pathway, a congenital thing, like a shortcut between the atria and ventricles that bypasses the normal AV node,
an accessory pathway,
right? And if electricity travels forward down that pathway during normal rhythm, you get that classic delta wave on the ECG, that sort of slurred upstroke on the QRS. That combo is wolf parkinson white syndrome or WPW. AVNRT on the other hand, that's a short circuit inside the AV node itself and focal AT. That just means there's one specific spot in the atrium that's firing off way too fast.
That clarifies the different players nicely. But let's bring it back to the patient sitting in front of you.
What are we actually trying to achieve when we treat SVT? What are the main goals?
Good question. We really think about goals in sort of two stages plus one absolutely vital overall aim.
So, In the acute stage, when someone presents with SVT, the immediate goal is usually to get them back into a normal sinus rhythm, especially for those re-entrant ones like AVRT and AVNRT rhythm control is almost always possible there, right?
But for AF, flutter or atrial tacicardia, if getting back to sinus rhythm isn't happening right away or maybe it's not the best long-term plan for that patient, then the acute bill shifts. It becomes controlling the rate of the SVT,
slowing it down.
Exactly. Slowing that fast ventricular rate down to something safer and frankly more comfortable for the patient. Then thinking longer term, the objective is to stop the arhythmia from coming back or at the very least to significantly reduce how often it happens and how much it impacts the patient's life. Reduce the arhythmia burden we call it. And overarching all of this particularly for AF and atrial flutter is that crucial goal reducing the risk of thrombolic events specifically stroke. That's absolutely paramount.
Okay. So before we jump into treatments, it sounds like getting the diagnosis right is key. What investigations are essential? What clues do we need to gather?
Absolutely. Diagnosis first. It's like putting pieces of a puzzle together. We always start with a really detailed patient history.
What kind of things are you asking?
We want to know about the episodes. When did they start? How often? How long do they last? Any specific triggers, things like alcohol, caffeine, exercise, maybe symptoms of an overactive thyroid. Understanding the pattern helps point us towards the likely type of SVT. Though It's worth noting lots of patients don't actually have consistent triggers. It just happens, right?
Then the absolutely critical piece, we need to document the arrhythmia itself. The gold standard is catching it on a 12 lead ECG while it's happening.
But what if it comes and goes?
Exactly. For those intermittent cases, a halter monitor worn for 24, maybe 48 hours or even a longerterm loop recorder can be invaluable for actually capturing the rhythm disturbance. And finally, echo cardiography, an ultrasound of the heart. This is essential. It lets us look at the heart structure and function, things like left ventricular function, the size of the left atrium, how the valves are working.
Why is the echo so important?
Because those findings heavily influence our treatment choices, especially around things like anti-coagulation and certain anti-arithmic drugs. Some drugs are unsafe if there's underlying structural heart disease.
Okay, that makes perfect sense. Diagnosis sorted.
Now, let's get into treatment. And maybe surprisingly, let's start before medications. What are the key non-drug strategies?
Harder to slow down
often. Yes. And second, and this impacts treatment, the threshold for considering catheter ablation is generally lower for atrial flutter. It tends to respond really well to ablation, often providing a long-term fix.
Makes sense.
And just quickly on those other usually benign SVTs, the mechanisms, AVRT is caused by an extra electrical pathway, a congenital thing, like a shortcut between the atria and ventricles that bypasses the normal AV node,
an accessory pathway,
right? And if electricity travels forward down that pathway during normal rhythm, you get that classic delta wave on the ECG, that sort of slurred upstroke on the QRS. That combo is wolf parkinson white syndrome or WPW. AVNRT on the other hand, that's a short circuit inside the AV node itself and focal AT. That just means there's one specific spot in the atrium that's firing off way too fast.
That clarifies the different players nicely. But let's bring it back to the patient sitting in front of you.
What are we actually trying to achieve when we treat SVT? What are the main goals?
Good question. We really think about goals in sort of two stages plus one absolutely vital overall aim.
So, In the acute stage, when someone presents with SVT, the immediate goal is usually to get them back into a normal sinus rhythm, especially for those re-entrant ones like AVRT and AVNRT rhythm control is almost always possible there, right?
But for AF, flutter or atrial tacicardia, if getting back to sinus rhythm isn't happening right away or maybe it's not the best long-term plan for that patient, then the acute bill shifts. It becomes controlling the rate of the SVT,
slowing it down.
Exactly. Slowing that fast ventricular rate down to something safer and frankly more comfortable for the patient. Then thinking longer term, the objective is to stop the arhythmia from coming back or at the very least to significantly reduce how often it happens and how much it impacts the patient's life. Reduce the arhythmia burden we call it. And overarching all of this particularly for AF and atrial flutter is that crucial goal reducing the risk of thrombolic events specifically stroke. That's absolutely paramount.
Okay. So before we jump into treatments, it sounds like getting the diagnosis right is key. What investigations are essential? What clues do we need to gather?
Absolutely. Diagnosis first. It's like putting pieces of a puzzle together. We always start with a really detailed patient history.
What kind of things are you asking?
We want to know about the episodes. When did they start? How often? How long do they last? Any specific triggers, things like alcohol, caffeine, exercise, maybe symptoms of an overactive thyroid. Understanding the pattern helps point us towards the likely type of SVT. Though It's worth noting lots of patients don't actually have consistent triggers. It just happens, right?
Then the absolutely critical piece, we need to document the arrhythmia itself. The gold standard is catching it on a 12 lead ECG while it's happening.
But what if it comes and goes?
Exactly. For those intermittent cases, a halter monitor worn for 24, maybe 48 hours or even a longerterm loop recorder can be invaluable for actually capturing the rhythm disturbance. And finally, echo cardiography, an ultrasound of the heart. This is essential. It lets us look at the heart structure and function, things like left ventricular function, the size of the left atrium, how the valves are working.
Why is the echo so important?
Because those findings heavily influence our treatment choices, especially around things like anti-coagulation and certain anti-arithmic drugs. Some drugs are unsafe if there's underlying structural heart disease.
Okay, that makes perfect sense. Diagnosis sorted.
Now, let's get into treatment. And maybe surprisingly, let's start before medications. What are the key non-drug strategies?
Yeah, there are some powerful non-farmacologic options. A major one especially for AF and atrial flutter is electrical cardio version, right? Delivering a synchronized electrical shock to reset the heart's rhythm. Modern machines use bifphasic energy which is good because it lets us use lower energy levels making it safer. Now most SVTs apart from AF and flutter often respond well to drugs first but cardioversion is really important when a tacic cardia is causing serious problems. like hemodynamic instability, heart failure symptoms, or anggina, especially if meds aren't working quickly. It's also a useful tool for persistent AF or flutter, maybe before starting long-term meds or considering ablation.
How successful is it?
Initially, pretty good for AF, maybe 70 to 90% success in restoring sinus rhythm right then and there. But here's the catch. Without ongoing anti-riythmic drug therapy, only about 20% of those patients are still in sinus rhythm a year later.
Oh, wow. So, it's often not a long-term fix. on its own
generally not for AF. No, it's more like hitting the reset button. That long-term success rate does improve maybe to 50 65% if you add a drug like amodderone afterwards to help maintain the rhythm. Now, okay, for everyone listening, especially you PBC candidates, this next bit is super important. The rules around anti-coagulation for cardio version,
right? The blood thinners.
Yes. If a patient has AF or atrial flutter that's lasted 48 hours or more, or if they have a CH2 score of two or higher and the arhythmia has been there 12 hours or more
or if they've had a TIA or stroke in the last 6 months, they must be adequately anti-coagulated for at least three weeks before the cardio version.
Three weeks before. And remind us quickly about Chad 2.
Sure. Chad 2 helps estimate stroke risk. C is congestive heart failure. H for hypertension. A for age over 75. D for diabetes. Those are all one point. And S is prior stroke or TIA. That gets two points.
Got it?
Now, if the cardio version is more urgent, there's an alternative. You can start anti-coagulation then do a transissophageal echo cardiogram a te
looking for clots in the atrium
exactly if the tea is clear you can proceed with cardio version sooner but regardless of how you get there anti-coagulation must continue for a minimum of 4 weeks after the procedure
4 weeks after why so long
because the atrium can be stunned after cardioversion it doesn't contract well immediately so the risk of clot formation and stroke is still high during that recovery period
critical safety point okay what other non-drug opt are there.
The other major player is catheter ablation. This is a more invasive procedure where catheters are guided into the heart. Energy usually radio frequency which heats tissue or cryothermal which freezes it is applied very precisely to target the specific heart tissue causing the arhythmia. Essentially you're creating tiny scars to block or eliminate the abnormal electrical circuits. There are even newer techniques like pulse field ablation emerging.
And how effective is ablation?
It really depends on the type of SVT. For those re-entrant tech cardias, AVNRT and AVRT and for focal atrial teacardia, ablation is incredibly effective. We're talking cure rates often in the 90 to 98% range.
Wow. Cure rates.
Yes. With relatively low risk compared to say AF ablation. That's why the threshold to recommend ablation for these is quite low. It's strongly recommended for WPW with fast pre-exited SVT and definitely first lane consideration for anyone with recurrent symptomatic AVRT, AVNRT or focal. For typical atrial flutter, it's also highly successful around 95% with low complication rates. So, it's considered first line for most flutter patients.
Okay. So, verificative for those. What about for AF?
For AF, it's a bit different. Ablation is definitely a strong option for patients who are symptomatic despite trying anti-arithmic drugs or for those who just don't want to be on long-term meds.
How successful is it?
Initially, pretty good for AF, maybe 70 to 90% success in restoring sinus rhythm right then and there. But here's the catch. Without ongoing anti-riythmic drug therapy, only about 20% of those patients are still in sinus rhythm a year later.
Oh, wow. So, it's often not a long-term fix. on its own
generally not for AF. No, it's more like hitting the reset button. That long-term success rate does improve maybe to 50 65% if you add a drug like amodderone afterwards to help maintain the rhythm. Now, okay, for everyone listening, especially you PBC candidates, this next bit is super important. The rules around anti-coagulation for cardio version,
right? The blood thinners.
Yes. If a patient has AF or atrial flutter that's lasted 48 hours or more, or if they have a CH2 score of two or higher and the arhythmia has been there 12 hours or more
or if they've had a TIA or stroke in the last 6 months, they must be adequately anti-coagulated for at least three weeks before the cardio version.
Three weeks before. And remind us quickly about Chad 2.
Sure. Chad 2 helps estimate stroke risk. C is congestive heart failure. H for hypertension. A for age over 75. D for diabetes. Those are all one point. And S is prior stroke or TIA. That gets two points.
Got it?
Now, if the cardio version is more urgent, there's an alternative. You can start anti-coagulation then do a transissophageal echo cardiogram a te
looking for clots in the atrium
exactly if the tea is clear you can proceed with cardio version sooner but regardless of how you get there anti-coagulation must continue for a minimum of 4 weeks after the procedure
4 weeks after why so long
because the atrium can be stunned after cardioversion it doesn't contract well immediately so the risk of clot formation and stroke is still high during that recovery period
critical safety point okay what other non-drug opt are there.
The other major player is catheter ablation. This is a more invasive procedure where catheters are guided into the heart. Energy usually radio frequency which heats tissue or cryothermal which freezes it is applied very precisely to target the specific heart tissue causing the arhythmia. Essentially you're creating tiny scars to block or eliminate the abnormal electrical circuits. There are even newer techniques like pulse field ablation emerging.
And how effective is ablation?
It really depends on the type of SVT. For those re-entrant tech cardias, AVNRT and AVRT and for focal atrial teacardia, ablation is incredibly effective. We're talking cure rates often in the 90 to 98% range.
Wow. Cure rates.
Yes. With relatively low risk compared to say AF ablation. That's why the threshold to recommend ablation for these is quite low. It's strongly recommended for WPW with fast pre-exited SVT and definitely first lane consideration for anyone with recurrent symptomatic AVRT, AVNRT or focal. For typical atrial flutter, it's also highly successful around 95% with low complication rates. So, it's considered first line for most flutter patients.
Okay. So, verificative for those. What about for AF?
For AF, it's a bit different. Ablation is definitely a strong option for patients who are symptomatic despite trying anti-arithmic drugs or for those who just don't want to be on long-term meds.
It's often not a complete cure in the same way as for AVNRT or flutter, but it can significantly reduce the arhythmia burden, meaning fewer episodes, shorter episodes, less severe symptoms. Success rates tend to be higher for peroxismal AF, the kind that comes and goes.
Are there risks with ablation?
Yes, like any invasive procedure, there are risks. Things like bleeding or bruising at the catheter insertion site, damage to blood vessels, cardiac tamponade, bleeding around the heart, stroke, and a very rare but serious complication called an atrial esophageal fistula.
Fistula.
Yeah. An abnormal connection between the atrium and the esophagus. It can develop maybe two to six weeks after the procedure, often presenting with fever, chest pain, or difficulty swallowing. It's rare, but something we watch for. Often PPIs are prescribed postablation, partly to reduce potential GI irritation.
Good to know. Any other non-drug approaches?
Just briefly, there's perccutaneous left atrial appendage occlusion or LAOO. This involves placing a device to close off a small pouch in the left atrium called the appendage where most stroke-causing clots form in AF. This is really reserved for a very small specific group of patients. Those with AF who are at high stroke risk but have an extremely high irreversible risk of bleeding. That means they absolutely cannot take long-term anti-coagulants. Think recurrent major bleeding like intraraanial bleeds.
So not a common procedure.
No. And the current Canadian Cardiovascular Society guidelines give it a weak recommendation based on lowquality evidence. So it's an option but a niche one.
Okay, that covers the non-farmacologic side really well.
Now let's switch gears to medications. This is often, you know, the cornerstone especially for long-term management of AF and flutter. Let's start with that big question, rate control versus rhythm control. When do we choose which path?
Yeah, this is a fundamental decision. The big firm trial really shaped our thinking here. It showed that for many older patients, especially those who were asymptomatic or had only minimal symptoms from their AF, simply controlling the heart rate was just as good as trying to maintain a normal rhythm in terms of preventing stroke or death.
So, rhythm control isn't always necessary or better.
Exactly. It told us we don't always need to be aggressive about forcing sinus rhythm, particularly if the patient feels fine with rate control. However, there are definitely situations where rhythm control should be the goal. If patients have significant symptoms despite rate control, if they're younger and asymptomatic, or if there's concern about tech cardia related cardiammyopathy where the fast heart rate itself weakens the heart muscle and importantly, the current CCS guidelines actually recommend pursuing rhythm control in patients with recently diagnosed AF defined as within the last year because studies suggest better outcomes including stroke and mortality in that group.
Okay. So if we are aiming for rhythm control what are the main drug options?
We have several classes of anti-arithmic drugs. The class IC agents like fleconide and propifone are options. They can be used acutely for chemical cardioversion or for long-term maintenance therapy. Now listen up PBC candidates. This is absolutely critical. Fleanide and propenone are contraindicated. Do not use them in patients who had coronary artery disease or any any structural heart disease like significant left ventricular hypertrophy or reduced ejection fraction.
Why is that? What's the danger?
The danger is proarythmia. In a structurally abnormal heart, these drugs can actually cause potentially lethal ventricular arhythmias. It's a major safety issue. Also, another key point, if you use a class IC agent for AF or flutter, you must co-prescribe either a beta blocker or a non dihydroparadin calcium channel blocker like diliasm or verapamil.
Why the combo? It's a safety net.
Are there risks with ablation?
Yes, like any invasive procedure, there are risks. Things like bleeding or bruising at the catheter insertion site, damage to blood vessels, cardiac tamponade, bleeding around the heart, stroke, and a very rare but serious complication called an atrial esophageal fistula.
Fistula.
Yeah. An abnormal connection between the atrium and the esophagus. It can develop maybe two to six weeks after the procedure, often presenting with fever, chest pain, or difficulty swallowing. It's rare, but something we watch for. Often PPIs are prescribed postablation, partly to reduce potential GI irritation.
Good to know. Any other non-drug approaches?
Just briefly, there's perccutaneous left atrial appendage occlusion or LAOO. This involves placing a device to close off a small pouch in the left atrium called the appendage where most stroke-causing clots form in AF. This is really reserved for a very small specific group of patients. Those with AF who are at high stroke risk but have an extremely high irreversible risk of bleeding. That means they absolutely cannot take long-term anti-coagulants. Think recurrent major bleeding like intraraanial bleeds.
So not a common procedure.
No. And the current Canadian Cardiovascular Society guidelines give it a weak recommendation based on lowquality evidence. So it's an option but a niche one.
Okay, that covers the non-farmacologic side really well.
Now let's switch gears to medications. This is often, you know, the cornerstone especially for long-term management of AF and flutter. Let's start with that big question, rate control versus rhythm control. When do we choose which path?
Yeah, this is a fundamental decision. The big firm trial really shaped our thinking here. It showed that for many older patients, especially those who were asymptomatic or had only minimal symptoms from their AF, simply controlling the heart rate was just as good as trying to maintain a normal rhythm in terms of preventing stroke or death.
So, rhythm control isn't always necessary or better.
Exactly. It told us we don't always need to be aggressive about forcing sinus rhythm, particularly if the patient feels fine with rate control. However, there are definitely situations where rhythm control should be the goal. If patients have significant symptoms despite rate control, if they're younger and asymptomatic, or if there's concern about tech cardia related cardiammyopathy where the fast heart rate itself weakens the heart muscle and importantly, the current CCS guidelines actually recommend pursuing rhythm control in patients with recently diagnosed AF defined as within the last year because studies suggest better outcomes including stroke and mortality in that group.
Okay. So if we are aiming for rhythm control what are the main drug options?
We have several classes of anti-arithmic drugs. The class IC agents like fleconide and propifone are options. They can be used acutely for chemical cardioversion or for long-term maintenance therapy. Now listen up PBC candidates. This is absolutely critical. Fleanide and propenone are contraindicated. Do not use them in patients who had coronary artery disease or any any structural heart disease like significant left ventricular hypertrophy or reduced ejection fraction.
Why is that? What's the danger?
The danger is proarythmia. In a structurally abnormal heart, these drugs can actually cause potentially lethal ventricular arhythmias. It's a major safety issue. Also, another key point, if you use a class IC agent for AF or flutter, you must co-prescribe either a beta blocker or a non dihydroparadin calcium channel blocker like diliasm or verapamil.
Why the combo? It's a safety net.